



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b> C12N 15/13, C07K 13/00 C12N 15/62, C12P 21/08 A61K 39/395, 49/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/15683  <b>(43) International Publication Date:</b> 17 September 1992 (17.09.92)
<b>(21) International Application Number:</b> PCT/EP92/00480  <b>(22) International Filing Date:</b> 4 March 1992 (04.03.92)  <b>(30) Priority data:</b> 91103389.2 6 March 1991 (06.03.91) EP <b>(34) Countries for which the regional or international application was filed:</b> AT et al.  <b>(71) Applicant (for all designated States except US):</b> MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG[DE/DE]; Frankfurter Str. 250, D-6100 Darmstadt (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> BENDIG, Mary, M. [US/GB]; 64 Solent Road, West Hamstead, London NW6 1TX (GB). KETTLEBOROUGH, Catherine, A. [GB/GB]; 28 Milton St., Watford, Herts, WD2 5W (GB). SALDANHA, José [GB/GB]; 22 Lincoln Way, Enfield, Middlesex EN1 1TE (GB).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), CS, DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES  <b>(57) Abstract</b>  The invention relates to new humanized monoclonal antibody comprising an artificial modified consensus sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The invention relates, furthermore, to corresponding humanized and chimeric monoclonal antibodies which are binding to epitopes of the Epidermal Growth Factor wherein the responsible hypervariable regions have the following amino acid sequence: <i>light chain</i> : CDR-1: -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-; CDR-2: -Asp-Thr-Ser-Asn-Leu-Ala-Ser-; CDR-3: -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-; <i>heavy chain</i> : CDR-1: -Ser-His-Trp-Met-His-; CDR-2: -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Glu-Lys-Phe-Lys-Ser-; CDR-3: -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-. The antibodies can be used for therapeutical and diagnostic purposes.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NI	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

## Humanized and Chimeric Monoclonal Antibodies

5

### TECHNICAL FIELD OF THE INVENTION

10

The invention relates to new humanized monoclonal antibodies comprising an artificial modified consensus sequence at least of the FRs in the variable region of the heavy chain of human immunoglobulins.

15

The invention relates, furthermore, to humanized and chimeric monoclonal antibodies which are binding to epitopes of the Epidermal Growth Factor. The invention discloses the amino acid sequences of the responding antigen-binding site for this receptor.

20

The invention relates to pharmaceutical compositions comprising the said antibodies for the purposes of treating tumors like melanoma, glioma or carcinoma. The said antibodies can be used also for diagnostic applications regarding locating and assessing the said tumors in vitro or in vivo.

25

The specification relates to several technical terms which are here defined as follows:

30

"Humanized" antibodies mean antibodies comprising FRs of the variable regions and constant regions of amino acids located in the light and heavy chain which derive from human sources whereas the hypervariable regions derive from non-human sources.

"Chimeric" antibodies mean antibodies comprising variable and hypervariable regions which derive from non-human sources whereas the constant regions derive from human origin.

"FRs" mean the framework regions of an antibody and are found within the variable regions. In these regions a certain alteration of amino acids occurs.

"CDRs" mean the complementarity determining or "hypervariable" regions of an antibody and are found within the variable regions. These regions represent the specific antigen-binding site and show an immense exchange of amino acids. CDRs are primarily responsible for the binding affinity of the antigen.

"Consensus sequence" means a non-naturally occurring amino acid sequence as light or heavy chain variable regions and is used as substitute for the originally present non-human heavy or light chain variable regions. The consensus sequences is synthetic and therefore an artificial sequence of the most common amino acids of a distinct class or subclass or subgroup of heavy or light chains of human immunoglobulins.

"EGF" and "EGFR" mean the Epidermal Growth Factor and its receptor.

"V<sub>L</sub>" regions mean light chain variable regions.

"V<sub>H</sub>" regions mean heavy chain variable regions.

## 5 BACKGROUND OF THE INVENTION

The murine monoclonal antibody 425 (Mab 425) was raised against the human A431 carcinoma cell line and found to bind to a polypeptide epitope on the external domain of the human  
10 epidermal growth factor receptor (EGFR). It was found to inhibit the binding of epidermal growth factor (EGF) at both low and high affinity EGFR sites (Murthy et al., 1987), Enhanced expression of EGFR is found to occur on malignant tissue from a variety of sources thus making Mab 425 a possi-  
15 ble agent for the diagnosis and therapeutic treatment of human tumors. Indeed, Mab 425 was found to mediate tumor cytotoxicity in vitro and to suppress tumor cell growth of epidermoid and colorectal carcinoma-derived cell lines in vitro (Rodeck et al., 1987). Radiolabelled Mab 425 has also  
20 been shown to bind to xenografts of human malignant gliomas in mice (Takahashi et al., 1987).

EGF is a polypeptide hormone which is mitogenic for epidermal and epithelial cells. When EGF interacts with sensitive  
25 cells, it binds to membrane receptors; the receptor EGF complexes cluster and then are internalized in endocytotic vesicles. This is responsible for the phenomenon of "down-regulation". EGF binding induces a tyrosine kinase activity of the receptor molecule and induces synthesis of DNA.

30

The EGF-receptor is a transmembrane glycoprotein of about 170,000 Daltons (Cohen, 1982). It is the gene product of the c-erb-B proto-oncogene (Downward et al., Nature, Vol. 307, pp. 521-527, 1984). The receptor exists in two kinetic forms:  
5 so-called low affinity and high-affinity receptors.

The A431 carcinoma cell line expresses abundant EGF-receptors on its cell surfaces, and thus has been used in many studies to generate anti-EGF-receptor antibodies. However, the recep-  
10 tors on A431 differ from those of other cell types in the carbohydrate moieties attached to the polypeptide. Thus many antibodies raised against A431 membranes are directed against carbohydrates which are not common to all forms of the receptor molecule (e.g. Schreiber, 1983).

Other monoclonal antibodies are reactive with the protein moiety of EGF-receptors. These antibodies display a variety of properties upon binding to EGF-receptors, presumably dependent on the particular portion of the receptor molecule  
20 bound, and the isotype of the antibody. Some antibodies mimic some of the effects of EGF (agonists) and some inhibit the effects (antagonists).

Expression of EGF-receptors has been implicated in the progression of tumor growth. The gene for the receptors has been found to be the cellular analogue of the avian viral oncogene v-erb-B (Ulrich, 1984). In addition an association has been detected between late stages of melanoma development and extra copies of the chromosome carrying the receptor gene  
25 (Koprowski et al., Somatic Cell and Molecular Genetics, Vol. 11, pp. 297-302, 1985).

Because of EGF-receptors are expressed on a wide variety of solid tumors they provide a suitable target for anti-tumor therapy. However, there is a need in the art for a suitable anti-receptor antibody. Many of the known antibodies have properties which would be deleterious if used as anti-tumor agents. For example, antibodies which mimic the effects of EGF could stimulate the progression of the tumor rather than arresting it. Other antibodies which only bind to high or low affinity receptors could be less than optimally effective because EGF could still exert its effect through the unbound receptors. Still other antibodies convert low affinity receptors to high affinity receptors, which could exacerbate tumor growth rather than inhibiting it. Thus there is a need in the art for an anti-EGF-receptor antibody which would be suitable for anti-tumor therapy.

Although murine MAbs have been used for therapeutic treatment in humans, they have elicited an immune response (Giorgi et al., 1983; Jaffers et al., 1986). To overcome this problem, several groups have tried to "humanize" murine antibodies. This can involve one of two approaches. Firstly, the murine constant region domains for both the light and heavy chain can be replaced with human constant regions. Such "chimeric" murine-human antibodies have been successfully constructed from several murine antibodies directed against human tumor-associated antigens (Sun et al., 1987; Whittle et al., 1987; Liu et al., 1987; Gillies and Wesolowski, 1990). This approach totally conserves the antigen-binding site of the murine antibody, and hence the antigen affinity, while conferring the human isotype and effector functions. In the second approach only the complementarity determining regions

(CDRs) from the mouse variable regions are grafted together with human framework regions (FRs) of both the light and heavy chain variable domains ( $V_L$  and  $V_H$ ). It is reasoned that this technique will transfer the critical and major portion of the antigen-binding site to the human antibody (Jones et al., 1986).

CDR grafting has been carried out for several rodent monoclonals (Jones et al., 1986; Reichmann et al., 1988; Verhoeyen et al.; 1988; Queen et al.; 1989; Co et al., 1991; Gorman et al., 1991; Maeda et al., 1991; Temptest et al., 1991). All retained their capacity to bind antigen, although the affinity was usually diminished. In most cases it was deemed necessary to alter certain amino acids in the human framework residues (FRs). Both chimeric and CDR grafted antibodies have proved superior to the mouse antibodies in the clinic (Hale et al., 1988; LoBuglio et al., 1989; Mathieson et al., 1990). However, a general teaching of which amino acids have to be changed, is not known and not completely predictable in any case.

EP 088 994 proposes the construction of recombinant DNA vectors comprising of a DNA sequence which codes for a variable domain of a light or a heavy chain of an immunoglobulin specific for a predetermined ligand. The application does not contemplate variations in the sequence of the variable domain.

EP 102 634 describes the cloning and expression in bacterial host organisms of genes coding for the whole or a part of human IgG heavy chain polypeptide, but does not contemplate variations in the sequence of the polypeptide.



EP 239 400 proposes that humanized antibodies can be obtained by replacing the antigen-binding site (hypervariable regions) of any human antibody by an antigen-binding site of a non-human, for example of a mouse or a rat antibody by genetech-  
5 nological methods.

Thus, following this teaching, human or humanized antibodies can be manufactured having specific antigen-binding sites which were not available up to now in antibodies originating  
10 from humans.

Chimeric antibodies can be obtained by replacing not only the CDRs but the whole variable regions of the light and heavy chains. Chimeric antibodies, however, can still be immuno-  
15 genic. Chimeric antibodies are, however, very useful for diagnostic purposes and optimizing humanized antibodies.

It could be shown that the affinity of the antigen-binding sites can be influenced by selective exchange of some single  
20 amino acids within the variable regions which are not directly part of the CDRs (Reichmann et al., 1988).

As consequence in the worst case, the binding affinity of the antigen can be completely lost if one works according to the  
25 teaching of the EP 239 400. This fact could be demonstrated by the inventors of the instant invention, who failed in constructing a correspondingly humanized antibody which was directed to epitopes of the EGF-receptor.

30 Therefore, it must be considered that the success of such a humanization depends on the constitution and conformation of the used variable regions and their interactions with the

corresponding antigen-binding site. Thus, it is not completely predictable whether or which modifications within the variable domains of the antibody are necessary in order to obtain or to improve the binding of the antigen to the antibody.

#### SUMMARY OF THE INVENTION

Thus, the invention has the object of providing a humanized monoclonal antibody which is, in particular, directed to the EGF-receptor, comprising an antigen-binding site of non-human sources and the FRs of the variable regions and constant regions of human origins, which are, if necessary, modified in a way that the specificity of the binding site can be conserved or restored.

In particular, the invention has the object of characterizing the hypervariable regions of the antigen-binding site of an antibody against the EGF-receptor and providing these CDRs within a humanized monoclonal antibody defined as above.

This antibody and its chimeric variant can play an important role as a therapeutic or diagnostic agent in order to combat tumors, as melanoma, glioma or carcinoma.

It has been found, that effective and specific humanized monoclonal antibodies can be easily obtained by using a consensus sequence of at least the heavy chain variable regions of human immunoglobulins. In particular, all those consensus sequences are suitable which have a good (at least 60-70 %, particularly 65-70 %) identity compared with the variable regions of the original non-human antibodies.

Furthermore, it has been found, that these consensus sequences have to be modified only to a low extent whereas sometimes much more modifications have to be undertaken using variable regions of naturally occurring human antibodies.

5 Often no or only a few modifications in the amino acid sequence are necessary according to the invention in order to receive a good specific antigen binding. Thus, only a few amino acids must be replaced in getting a perfect binding of the EGF-receptor to the preferred humanized antibody according to the invention, whereas no binding can be obtained here  
10 according to the teaching of the EP 239 400. The modifications which are necessary according to the invention can be indicated with 0 to 10 %, or preferably, 1 to 5 % related to the exchange of amino acids.

15

A humanized monoclonal antibody according to the invention has the following advantage: a consensus sequence which is a sequence according to the most common occurrence of amino acid on a distinct position of a chain of human immunoglobulin of a defined class or subclass or subgroup, can be synthesized as a whole or as a part without problems. There is no dependence on the detailed knowledge or availability of certain individual antibodies or antibody fragments. That means that a wide range of individually and naturally occurring antibody fragments can be covered by providing a very  
20 restricted number of consensus sequences which are cloned into corresponding expression vectors. A consensus sequence may be favorable with respect to the immunogenicity in comparison with individual natural sequences which are known to  
25 be sometimes epitopes for other antibodies (for example anti-idiotypic antibodies).  
30

Although only one preferred embodiment was made, a general principal teaching is disclosed according to the instant invention. It is not a mere accident with respect to the large number of possible sequences and combinations of sequences in the variable and hypervariable domains that the described teaching regarding the consensus sequence succeeded in constructing a humanized antibody directed to the EGF-receptor.

Furthermore, it has been found, that the heavy chains of the variable domains provide a greater contribution to the antigen-binding site than the corresponding light chains. Therefore, it is not necessary to modify in the same manner the light chain of a humanized antibody having a consensus sequence. This is an interesting aspect because it is known that the light chains in some known natural antibodies play the more important role than the corresponding heavy chains (see Williams et al., 1990).

Finally and above all, the invention provides for the first time the characterization, cloning and amplification by means of genetic engineering the antigen-binding site of a murine antibody against the EGF-receptor (MAb 425). Corresponding oligonucleotides could be synthesized which code for that antigen-binding site and for the whole variable domain of a humanized and chimeric monoclonal antibody. The invention provides, moreover, correspondingly effective expression vectors which can be used for the transformation of suitable eukaryotic cells.

30

Thus, the invention relates to a humanized monoclonal antibody comprising antigen bindings sites (CDRs) of non-human origin, and the FRs of variable regions and constant regions of light and heavy chains of human origin, characterized in that at least the FRs of the variable regions of the heavy chain comprise a modified consensus sequence of different variable regions of a distinct class or subgroup of a human immunoglobulin.

10 In particular, the invention relates to a humanized monoclonal antibody, wherein the FRs of the consensus sequence has a homology of at least 70 % compared with the amino acid sequence of the FRs of the variable region of the non-human antibody from which the antigen-binding sites originate.

15 In particular, the invention relates to a humanized monoclonal antibody, having the following properties:

- (a) binds to human EGF-receptors;
- 20 (b) inhibits binding of EGF to EGF-receptor;
- (c) inhibits the EGF-dependent tyrosine kinase activity of EGF-receptor;
- (d) inhibits the growth of EGF-sensitive cells.

25 In particular, the invention relates to a humanized monoclonal antibody, wherein the hypervariable regions of the antigen-binding sites comprise the following amino acid sequences:

30

**light chain**

CDR-1 -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-  
CDR-2 -Asp-Thr-Ser-Asn-Leu-Ala-Ser-  
5 CDR-3 -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

**heavy chain**

CDR-1 -Ser-His-Trp-Met-His-  
10 CDR-2 -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-Glu-  
Lys-Phe-Lys-Ser-  
CDR-3 -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-

15 In particular, the invention relates to a humanized mono-  
clonal antibody, wherein the FRs of the variable regions  
which are not related to the antigen-binding sites comprise  
the following amino acid sequence:

**light chain**

20 FR-1 -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-  
Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-  
FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-  
Ile-Tyr-  
25 FR-3 -Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-  
Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-Leu-Gln-  
Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-  
FR-4 -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

30

**heavy chain**

- 5 FR-1 -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-Lys-  
Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-Ser-Gly-  
Tyr-Thr-Phe-Thr (Ser) -
- FR-2 -Trp-Val-Arg (His) -Gln-Ala (Lys, His) -Pro (Val) -Gly-Gln-  
Gly-Leu-Glu-Trp-Ile (Val, Leu) -Gly-
- 10 FR-3 -Lys (Arg, His) -Ala (Val, Pro-Gly) -Thr-Met-Thr-  
Val (Ala, Pro, Gly) -Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-Met-  
Glu (Asn) -Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Val-  
Tyr-Tyr-Cys-Ala-Ser-
- FR-4 -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser-,

15 and wherein the amino acids listed in the brackets are alter-  
natives.

20 In particular, the invention relates to a humanized mono-  
clonal antibody, wherein the constant regions of the heavy  
chain comprise the amino acid sequence of a gamma-1 chain,  
and the constant regions of the light chain comprise the  
amino acid sequence of a kappa chain of a human immunoglobu-  
lin.

25 In particular, the invention relates to a humanized mono-  
clonal antibody, comprising a derivate of an amino acid  
sequence modified by amino acid deletion, substitution,  
addition or inversion within the variable and constant  
regions wherein the biological function of specific binding  
to the antigen is preserved.

30

Furthermore, the invention relates to an expression vector, suitable for transformation of host cells, characterized in that it comprises a DNA sequence coding for the variable and/or constant regions of the light and/or heavy chains of a humanized antibody.

Furthermore, the invention relates to humanized or chimeric monoclonal antibody, comprising hypervariable regions (CDRs) of antigen-binding sites of murine origin and the FRs of the variable regions of human or murine origin and constant regions of light and heavy chains of human origin, characterized in that the hypervariable regions comprise the following amino acid sequences,

**light chain**

CDR-1 -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-  
CDR-2 -Asp-Thr-Ser-Asn-Leu-Ala-Ser-  
CDR-3 -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

20

**heavy chain**

CDR-1 -Ser-His-Trp-Met-His-  
CDR-2 -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-Glu-  
Lys-Phe-Lys-Ser-  
CDR-3 -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-,

25

and wherein the constant regions of the heavy chain comprise the amino acid sequence of a gamma-1 chain, and the constant regions of the light chain comprise the amino acid sequence of a kappa chain of a human immunoglobulin.

30



In particular, the invention relates to a humanized monoclonal antibody according to claim 12, wherein the FRs of the variable regions which are not related to the antigen-binding sites, are of human origin and comprise the following amino acid sequence,

**light chain**

FR-1 -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-  
10 Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-  
FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-  
Ile-Tyr-  
FR-3 Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-  
Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-Leu-Gln-  
15 Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-  
FR-4 -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

**heavy chain**

20 FR-1 -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-Lys-  
Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-Ser-Gly-  
Tyr-Thr-Phe-Thr (Ser) -  
FR-2 -Trp-Val-Arg (His) -Gln-Ala (Lys, His) -Pro (Val) -Gly-Gln-  
Gly-Leu-Glu-Trp-Ile (Val, Leu) -Gly-  
25 FR-3 -Lys (Arg, His) -Ala (Val, Pro, Gly) -Thr-Met-Thr-  
Val (Ala, Pro, Gly) -Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-Met-  
Glu (Asn) -Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Val-  
Tyr-Tyr-Cys-Ala-Ser-  
FR-4 -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser-

30

In particular, the invention relates to a chimeric monoclonal antibody according to Claim 12, wherein the FRs of the variable regions which are not related to the antigen-binding site, are of murine origin and comprise the following amino acid sequences:

5

**light chain**

FR-1 -Gln-Ile-Val-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Met-Ser-Ala-  
10 Ser-Pro-Gly-Glu-Lys-Val-Thr-Met-Thr-Cys-  
FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Ser-Ser-Pro-Arg-Leu-Leu-  
Ile-Tyr-  
FR-3 -Gly-Val-Pro-Val-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-  
Ser-Tyr-Ser-Leu-Thr-Ile-Ser-Arg-Met-Glu-Ala-Glu-Asp-  
15 Ala-Ala-Thr-Tyr-Tyr-Cys-  
FR-4 -Phe-Gly-Ser-Gly-Thr-Lys-Leu-Glu-Ile-Lys-

**heavy chain**

20 FR-1 -Gln-Val-Gln-Leu-Gln-Gln-Pro-Gly-Ala-Glu-Leu-Val-Lys-  
Pro-Gly-Ala-Ser-Val-Lys-Leu-Ser-Cys-Lys-Ala-Ser-Gly-  
Tyr-Thr-Phe-Thr-  
FR-2 -Trp-Val-Lys-Gln-Arg-Ala-Gly-Gln-Gly-Leu-Glu-Trp-Ile-  
Gly-  
25 FR-3 -Lys-Ala-Thr-Leu-Thr-Val-Asp-Lys-Ser-Ser-Ser-Thr-Ala-  
Tyr-Met-Gln-Leu-Ser-Ser-Leu-Thr-Ser-Glu-Asp-Ser-Ala-  
Val-Tyr-Tyr-Cys-Ala-Ser-  
FR-4 -Trp-Gly-Gln-Gly-Thr-Thr-Leu-Thr-Val-Ser-Ser-

30

Moreover, the invention relates to an expression vector, suitable for transformation of host cells, characterized in that it comprises DNA sequences coding for the variable and/or constant regions of the light and/or heavy chains of a humanized or chimeric monoclonal antibody.

Furthermore, the invention relates to a process for the preparation of a humanized monoclonal antibody, comprising hypervariable regions (CDRs) of antigen-binding sites of non-human origin, and FRs of variable regions and constant regions of the light and heavy chains of human origin by cultivating transformed host cells in a culture medium and purification and isolation the expressed antibody proteins, characterized in

15

(a) synthesizing or partially synthesizing or isolating an oligonucleotide sequence which codes for an amino acid consensus sequence of different variable regions (FR-1 to FR-4) of a heavy chain of a class or a subgroup of a human immunoglobulin, wherein the used consensus sequence has a homology of at least 70 % compared with the amino acid sequence of the FRs of the variable regions of the non-human antibody from which the antigen-binding sites originate, and wherein the consensus sequence is modified by alterations of maximum 10 % of the amino acids in order to preserve the binding capability of the antigen to the hypervariable regions;

20

25

(b) synthesizing or partially synthesizing or isolating an oligonucleotide sequence which codes for an amino acid consensus sequence under the conditions given in (a) of

30

different variable regions (FR-1 to FR-4) of a light chain of a class or a subgroup of a human immunoglobulin, or, alternatively, which codes for a corresponding natural occurring amino acid sequence;

5

(c) in each case synthesizing or partially synthesizing or isolating an oligonucleotide sequence which codes for the amino acid sequence of the hypervariable regions (CDRs) of the light and heavy chain corresponding to the hypervariable regions of the basic non-human antibody;

10

(d) in each case synthesizing or partially synthesizing or isolating an oligonucleotide sequence which codes for the amino acid sequence of the constant regions of the light and heavy chain of a human immunoglobulin;

15

(e) constructing one or several expression vectors comprising in each case at least a promoter, a replication origin and the coding DNA sequences according to (a) to (d), wherein the DNA sequences coding for the light and heavy chains can be present together in one or, alternatively, in two or more different vectors,

20

and finally,

25

(f) transforming the host cells with one or more of the expression vectors according to (e).

30

In particular, the invention relates to a process, wherein DNA sequences are used coding for the following amino acid sequences which represent the hypervariable regions (CDRs):

**light chain**

CDR-1 -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-  
CDR-2 -Asp-Thr-Ser-Asn-Leu-Ala-Ser-  
5 CDR-3 -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

**heavy chain**

CDR-1 -Ser-His-Trp-Met-His-  
10 CDR-2 -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-Glu-  
Lys-Phe-Lys-Ser-  
CDR-3 -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-

15 In particular, the invention relates to a process, wherein  
DNA sequences are used coding for the following amino acid  
sequences which represent the FRs of the variable regions :

**light chain**

20 FR-1 -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-  
Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-  
FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-  
Ile-Tyr-  
FR-3 -Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-  
25 Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-Leu-Gln-  
Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-  
FR-4 -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

30

**heavy chain**

- FR-1     -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-Lys-  
           Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-Ser-Gly-  
 5           Tyr-Thr-Phe-Thr(Ser)-
- FR-2     -Trp-Val-Arg(His)-Gln-Ala(Lys,His)-Pro(Val)-Gly-Gln-  
           Gly-Leu-Glu-Trp-Ile(Val,Leu)-Gly-
- FR-3     -Lys(Arg,His)-Ala(Val,Pro,Gly)-Thr-Met-Thr-  
           Val(Ala,Pro,Gly)-Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-Met-  
 10          Glu(Asn)-Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Val-  
           Tyr-Tyr-Cys-Ala-Ser-
- FR-4     -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser

Moreover, the invention relates to a process for the prepara-  
 15        tion of a chimeric monoclonal antibody having the biological  
       function of binding to epitopes of the EGF-receptor, compris-  
       ing hypervariable regions (CDRs) of antigen-binding sites and  
       FRs of variable regions of murine origin        and FRs of  
       variable regions of murine origin and constant regions of the  
 20       light and heavy chains of human origin by cultivating trans-  
       formed host cells in a culture medium and purification and  
       isolation the expressed antibody proteins, characterized in  
       that the host cells are transformed with expression vectors  
       according to one of the expression vectors.

25       Furthermore, the invention relates to a pharmaceutical compo-  
       sition comprising a humanized or chimeric monoclonal anti-  
       body.

30       Furthermore, the invention relates to the use of humanized or  
       chimeric antibody for the manufacture of a medicament  
       directed to tumors.

Finally, the invention relates to the use of humanized or chimeric antibody for diagnostic locating and assessing tumor growth.

5 To sum up, the invention relates to a monoclonal antibody comprising a consensus sequence of variable regions of a heavy chain of a class or a subgroup of human immunoglobulins.

10 The entire disclosures of all applications, patents and publications, if any, cited above and below, and of corresponding European Patent application 91 103 389.2, filed March 6, 1991, are hereby incorporated by reference.

15 Microorganisms and plasmids used in the invention:

(a) **pRVL425 (= HCMV-RV<sub>L</sub>b425-k)**, deposited on February 1, 1991, according to the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen (DSM) under the accession No.  
20 DMS 6340. The expression vector contains the sequences of the hypervariable regions (CDRs) of the murine antibody 425 and the FRs of the variable region and the constant (kappa) region of the light chain of the humanized antibody. R is standing for "reshaped".

25

(b) **pRVH425 (= HCMV-RV<sub>H</sub>g425-γ)**, deposited on February 1, 1991, according to the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen (DSM) under the accession No.  
30 DSM 6339. The expression vector contains the sequences of the hypervariable regions (CDRs) of the murine antibody

425 and the FRs of variable region and constant (gamma-1) region of the heavy chain of the humanized antibody. R is standing for "reshaped".

5 (c) **pCVL425 (= HCMV-CV<sub>L</sub>425-k)**, deposited on February 1, 1991, according to the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen (DSM) under the accession No. DSM 6338. The expression vector contains the sequences of the FRs and hypervariable regions (CDRs) of the light  
10 chain variable region of the murine antibody 425 and the constant (kappa) region of the light chain of human immunoglobulin. C is standing for chimeric.

(d) **pCVH425 (= HCMV-CV<sub>H</sub>425-γ)**, deposited on February 1, 1991,  
15 according to the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen (DSM) under the accession No. DSM 6337. The expression vector contains the sequences of the FRs and hypervariable regions (CDRs) of the light chain variable region of the murine antibody 425 and the  
20 constant region of the light chain of the human gamma-1 immunoglobulin. C is standing for chimeric.

(e) **Hybridoma cell line 425**, deposited on January 26, 1988, according to Budapest Treaty at the American Type Culture  
25 Collection (ATCC) under the accession No. HB 9629. The cell line produces the murine antibody 425 which is directed to the EGF-receptor.



Other biological materials:

Other microorganisms, cell lines, plasmids, promoters, resistance markers, replication origins or other fragments of  
5 vectors which are mentioned in the application are commercially or otherwise generally available. Provided that no other hints in the application are given, they are used only as examples and are not essential according to the invention and can be replaced by other suitable tools and biological  
10 materials, respectively.

Bacterial hosts are preferably used for the amplification of the corresponding DNA sequences. Examples for these host are: E. coli or Bacillus.

15 Eukaryotic cells like COS (CV1 origin SV40) or CHO (Chinese hamster ovary) cells or yeasts, for example, are preferred in order to produce the humanized and chimeric antibodies according to the invention. COS and CHO cells are preferred.

20 General methods for manufacturing:

The techniques which are essential according to the invention are described in detail in the specification.

25 Other techniques which are not described in detail correspond to known standard methods which are well known to a person skilled in the art or are described more in detail in the cited references and patent applications and in standard  
30 literature.

Brief descriptions of the Figures

**Fig. 1** Schematic representations of the vectors used for the expression of chimeric and reshaped human antibodies. Restriction sites used in the construction of the expression plasmids are marked. The variable region coding sequences are represented by the dark boxes, constant regions by the light boxes, the HCMV promoter and enhancer by the hatched boxes, and the nucleotide fragment from the plasmid pSVneo by the speckled boxes. The directions of transcription are represented by arrows.

**Fig. 2** The nucleotide and amino acid sequences of the  $V_H425$  (A), and  $V_L425$  (B) cDNA as cloned into pUC18. The amino acids contributing to the leader are underlined and CDRs are indicated by brackets. The splice sites between the variable regions and constant regions are also shown. The front and back PCR-primers and their annealing sites, used in the construction of the genes coding for the chimeric antibodies, are shown.

**Fig. 3** The nucleotide and amino acid sequences of the synthesized gene fragment coding for reshaped human  $V_Ha425$ . The leader sequence is underlined and residues contributing to the CDRs are bracketed.

**Fig. 4** Comparison of the amino acid sequences of mouse and reshaped human 425 variable regions. Panel A shows the sequences of mouse  $V_L$  ( $V_L425$ ) and reshaped human  $V_LS$  ( $RV_La425$  and  $RV_Lb425$ ). Panel B shows the sequences

of mouse  $V_H$  ( $V_H425$ ) and reshaped human  $V_{Hs}$  ( $RV_{Ha}425$ ,  $RV_{Hb}425$ ,  $RV_{Hc}425$ ,  $RV_{Hd}425$ ,  $RV_{He}425$ ,  $RV_{Hf}425$ ,  $RV_{Hg}425$ ,  $RV_{Hh}425$ , and  $RV_{Hi}425$ ). The FRs and CDRs are indicated. Amino acids are numbered according to Kabat et al., 1987.

**Fig. 5** Molecular model of the mouse MAb 425 variable regions.

**Fig. 6** Detection of binding to EGFR by ELISA. Antigen-binding activity was assayed in dilutions of transfected COS cell supernatants and plotted as optical density at 450 nm against concentration of IgG (quantitated by ELISA, see Materials and Methods). All versions of reshaped human  $V_H$  regions were cotransfected with  $RV_{La}425$  and are represented as follows:  $RV_{Ha}425$   $\Delta$ ,  $RV_{Hb}425$   $\circ$ ,  $RV_{Hc}425$   $\Delta$ ,  $RV_{Hd}425$   $\otimes$ ,  $RV_{He}425$   $\square$ ,  $RV_{Hf}425$   $\boxtimes$ ,  $RV_{Hg}425$   $\square$ ,  $RV_{Hh}425$   $\circ$ ,  $RV_{Hi}425$   $\circ$ ,  $RV_{Hb}425$  co-transfected with  $RV_{La}425$  is represented as  $\blacklozenge$ . A co-transfection of the chimeric  $VL425$  and  $VH425$  are represented as  $\bullet$ .

**Fig. 7** Competition for binding to antigen. Panel A shows competition between labelled mouse 425 antibody and (1) unlabelled mouse 425 antibody (+) and (2) chimeric 425 antibody ( $\bullet$ ) produced by COS cells after co-transfection with HCMV-CV<sub>L</sub>425-kappa and HCMV-C<sub>H</sub>425-gamma-1. Panel B shows competition between labelled mouse 425 antibody and (1) unlabelled mouse 425 antibody (+) and (2) the reshaped human 425 antibodies

produced by COS cells after co-transfection with HCMV-RV<sub>L</sub>a425-kappa and HCMV-RV<sub>H</sub>i425-gamma-1 (○), and with HCMV-RV<sub>L</sub>a425-kappa and HCMV-RV<sub>H</sub>g425-gamma-1 (□). In each case, the horizontal axis represents the concentration of inhibitor (ng/ml). The vertical axis represents percentage of inhibition of binding.

**Fig. 8** An examination of the effects of different reshaped human V<sub>L</sub> regions on antigen-binding. Panel A shows antigen-binding by reshaped human antibodies produced in COS cells transfected with HCMV-CV<sub>L</sub>425-kappa and HCMV-CV<sub>H</sub>425-gamma-1 (●), HCMV-RV<sub>L</sub>a425-kappa and HCMV-RV<sub>H</sub>g425-gamma-1 (□), HCMV-RV<sub>L</sub>b425-kappa and HCMV-RV<sub>H</sub>g425-gamma-1 (■), HCMV-RV<sub>L</sub>a425-kappa and HCMV-RV<sub>H</sub>c425-gamma-1 (Δ), and HCMV-RV<sub>L</sub>b425-kappa and HCMV-RV<sub>H</sub>c425-gamma-1 (▲). Panel B shows competition for binding to antigen between labelled mouse 425 antibody and (1) unlabelled mouse 425 antibody (+) and (2) reshaped human 425 antibodies produced in COS cells co-transfected with HCMV-V<sub>L</sub>a425-kappa and HCMV-V<sub>H</sub>g425-gamma-1 (□) and with HCMV-V<sub>L</sub>b425-kappa and HCMV-V<sub>H</sub>g425-gamma-1 (■). In panel A, the vertical axis represents the optical density at 450 nm (OD<sub>450</sub>) and the horizontal axis represents the concentration of IgG (ng/ml). In panel B, the horizontal axis represents the concentration of inhibitor (ng/ml) and the vertical axis represents percentage of inhibition of binding.

5 **Fig. 9** Panel A: Analysis of reshaped (lanes 1, 2), chimeric (lane 3) and murine (lane 4) MAb 425 by SDS-PAGE under non-reducing conditions (a) and under reducing conditions (b). Reshaped (lanes 7, 8), chimeric (lane 9) and murine (lane 10). Lanes 5, 6, 11, and 12 are MW markers.

Panel B: Purification by gel filtration of reshaped MAb 425 on Superose 12. Peak 2 represents IgG.

10

**Fig. 10** Competitive binding of murine, chimeric and reshaped MAb 425 to EGF-receptor (EGFR). The vertical axis represents the ratio bound (MAb) to total (MAb) in % (% bound/total). The horizontal axis represents the concentration of antibody (mol/l [log]).

15

∇ means MAb 425 murine  
○ means MAb 425 chimeric  
●, ▼ mean MAb 425 reshaped

20

**Fig. 11** Competition of EGF and antibodies to EGF-receptor. The vertical axis represents % bound/total (MAb). The horizontal axis represents the concentration of antibody (mol/l [log]).

25

○ means MAb 425 murine  
Δ, ∇, □ mean MAb 425 reshaped

30

## DETAILED DESCRIPTION

Cloning and sequencing of variable region genes of MAb 425:

5 From the cDNA synthesis and cloning using the kappa chain primer, 300-400 colonies are preferably picked for screening. From the cDNA synthesis and cloning using the gamma-2a primer, 200-300 colonies are preferably for screening. After screening by hybridization using the two respective cloning  
10 primers, 20-30 light chain colonies and 10-20 heavy chain colonies give strong signals. Plasmid DNA is isolated from these colonies and analyzed by usual and commercially available restriction enzyme digests to determine the size of the cDNA inserts. Clones that appear to have inserts 400-500 bp  
15 or 500-600 bp for  $V_L$  and  $V_H$  cloning, respectively, are selected as candidates for sequencing. Three  $V_L$  clones and three  $V_H$  clones are sequenced on both strands using M13 universal and reverse sequencing primers. Of the three possible  $V_L$  clones sequenced, one codes for a complete variable  
20 region and the others appears to code for unrelated peptides. Two of the  $V_H$  clones code for identical  $V_H$  regions while the other appears to code for the  $V_H$  region with the intron between the leader sequence and FR-1 still present. Apart  
25 from the intron, the third  $V_H$  clone contains coding sequence identical to that of the first two clones. To verify the sequence of the  $V_L$  region, three more cDNA clones containing inserts of the appropriate size are sequenced. Two of these give sequences in agreement with the first  $V_L$  clone. The third  
30 is an unrelated DNA sequence. In the clones sequenced, not

all of the original primer sequence are present. The extent of the deletions varies from clone to clone. These deletions, which probably occur during cDNA synthesis and cloning, may decrease the efficiency of the colony screening.

5

The  $V_L$  and  $V_H$  genes for MAb 425 are shown in Figure 2. The amino acid sequence of the 425  $V_L$  and  $V_H$  regions, are compared to other mouse variable regions in the Kabat data base (Kabat et al., 1987). The  $V_L$  region can be classified into the mouse  
10 kappa chain variable region subgroup IV or VI. Within the FRs, the 425  $V_L$  region has an approximately 86 % identity to the consensus sequence for mouse kappa subgroup IV and an approximately 89 % identity to subgroup VI. The 425  $V_L$  region  
15 appear to use the JK4 segment. Examination of the  $V_H$  region shows an approximately 98 % identity to the FRs of the consensus sequence for mouse heavy chain subgroup II (B).

The right choice of a suitable class or subgroup of human  
20 immunoglobulin is dependent on the extent of the identity to the originally present chain in the non-human antibody. The identity of the deduced consensus sequence according to the present invention should be greater than 65 to 70 % compared with the sequence of the original non-human chain.

25

The consensus sequences of the heavy chains are preferred especially, however, the consensus sequence of human heavy chain subgroup I. However, for other antibodies, the consensus sequences of other human heavy chains are suitable. The  
30 preferred consensus sequences are modified. The possible exchange of amino acids is 0 to 10 % according to the invention, preferably 5 to 10 %.

Construction and expression of chimeric 425 antibody:

Before the cDNAs coding for the VL and VH regions can be used in the construction of chimeric 425 antibody, it is necessary to introduce several modifications at the 5'- and 3' ends. these include introducing appropriate restriction enzyme sites so that the variable region coding sequences can be conveniently subcloned into the HCMV expression vectors. It is necessary to re-create donor splice sites in the 3'-flanking regions so that the variable regions are spliced correctly and efficiently to the constant regions. The 5'-flanking regions are also modified to include a sequence that would create efficient initiation sites for translation by eukaryotic ribosomes (Kozak, 1987). These modifications are introduced using PCR primers. The used primers are indicated in Table 1.

**Table 1** Oligonucleotides used for cDNA cloning, construction of chimerics, and mutagenesis. Underlined sections denote bases that anneal to the human framework.

<u>Number</u>	<u>Sequence</u>	<u>Description</u>
1.	5'-GTAGGATCCTGGATGGTGGGAAGATG-3'	Light chain primer for cDNA synthesis.
2.	5'-GTAGGATCCAGTGGATAGACCGATG-3'	Heavy chain primer for cDNA synthesis.
3.	5'-CTCCAAGCTTGACCTCACCATGG-3'	Chimeric V <sub>H</sub> front primer.



<u>Number</u>	<u>Sequence</u>	<u>Description</u>
	4. 5'-TTGGATCCACTCACCTGAGGAGACTGTGA-3'	Chimeric V <sub>H</sub> back primer.
5	5. 5'-AGAAAGCTTCCACCATGGATTTTCAAGTG-3'	Chimeric V <sub>L</sub> front primer.
	6. 5'-GTAGATCTACTCACGTTTTATTTC AAC-3'	Chimeric V <sub>L</sub> back primer.
10	7. 5'- <u>ACCATCACCTGTAGTGCCAGCTCAAGTG</u> TAACTTACATGTATTGGTACCAGCAG-3'	Reshaped V <sub>L</sub> CDR-1 primer.
	8. 5'- <u>CTGCTGATCTACGACACATCCAACCTGGC</u> TTCTGGTGTGCCAAGC-3'	Resphaped V <sub>L</sub> CDR-2 primer.
15	9. 5'- <u>ACCTACTACTGCCAGCAGTGGAGTAGTCA-</u> CATATTCA <u>CGTTCGGCCAA</u> -3'	Resphaped V <sub>L</sub> CDR-3 primer.
	*	
	10. 5'-AGCGGTACCGACTACACCTTCACCATC-3'	Primer to intro- duce F71Y into RV <sub>L</sub> .
	* *	
20	11. 5'-ATACCTTCACATCCCACTG-3'	Primer to intro- duce S30T into RV <sub>H</sub> .
	* *	
25	12. 5'-CGAGTGGATTGGCGAGT-3'	Primer to intro- duce V48I into RV <sub>H</sub> .

<u>Number</u>	<u>Sequence</u>	<u>Description</u>
	* * *	
13.	5'-TTTAAGAGCAAGGCTACCATGACCGTGGA- CACCTCT-3'	Primer to intro- duce R66K, V67A, L71V into RV <sub>H</sub> .
	*	
14.	5'-CATGACCGTGGACACCTCT-3'	Primer to intro- duce L71V into RV <sub>H</sub> .

For each variable region cDNA two primers are preferably designed. In the front primers, 15 bases at the 3'-end of the primer are used to hybridize the primer to the template DNA while the 5'-end of the primer contains a HindIII site and the "Kozak" sequence. The back primers have a similar design with 15 bases at the 3'-end used to hybridize the primer to the template DNA and the 5'-end of the primer contains a BamHI site and a donor splice site. In the case of the light chain back primer, a BglII site is used instead of BamHI site because the cDNA coding for the V<sub>L</sub> contains an internal BamHI site (Figure 2). The PCR reaction is preferably carried out as described in the examples.

The PCR-modified V<sub>L</sub> region DNA is cloned into the HindIII-BamHI sites of the HCMV light chain expression vector as a HindIII-BglII fragment. This vector already contains the human genomic kappa constant region with the necessary splice acceptor site and poly(A<sup>+</sup>) sites. The entire PCR-modified V<sub>L</sub> fragment is sequenced using two primers that anneal to sites flanking the cloning site in the expression vector. Sequencing confirms that no errors have been incorporated during the

PCR step. The PCR-modified  $V_H$  DNA is cloned into the HCMV heavy chain expression vector as a HindIII-BamHI fragment and also sequenced to confirm the absence of PCR errors. A BamHI fragment containing the human genomic gamma-1 constant region is inserted into the HCMV-CV<sub>H</sub> vector on the 3'-side of the  $V_H$  region. This fragment contains the necessary acceptor splice site for the V-C splice to occur in vivo and the naturally occurring poly(A<sup>+</sup>) site.

The expression vectors containing the chimeric 425  $V_L$  and  $V_H$  regions are co-transfected into appropriate eukaryotic cells, preferably COS cells. After approximately 72 h of transient expression, the cell culture medium is assayed by ELISA for human IgG production and for binding to EGFR protein. Amounts of human IgG detected in the media vary from 100-400 ng/ml. The chimeric antibody produced binds well to EGFR protein in a standard antigen-binding ELISA thus confirming that the correct mouse variable regions has been cloned and sequenced.

Initial design, construction and expression or reshaped human 425 light and heavy chains:

In designing a reshaped human 425 antibody, most emphasis is placed on the  $V_H$  region since this domain is often the most important in antigen-binding (Amit et al., 1986; Verhoeyen et al., 1988). To select the human FRs on which to graft the mouse CDRs, the FRs of mouse MAb 425  $V_H$  region are compared with the FRs from the consensus sequences for all subgroups

of human  $V_H$  regions (Kabat et al., 1987). This comparison shows that the FRs of mouse MAb 425  $V_H$  are most like the FRs of human  $V_H$  subgroup I showing an approximately 73 % identity within the FRs and an approximately 65 % identity over the entire  $V_H$  regions.

A further comparison of the mouse 425  $V_H$  region with other mouse  $V_H$  regions from the same Kabat subgroups is carried out to identity any FR residues which are characteristic of MAb 425 and may, therefore, be involved in antigen binding. The residue at position 94 of the mouse MAb 425  $V_H$  region is a serine while in other  $V_H$  regions from mouse subgroup II (B), and also from human subgroup I, residue 94 is an arginine (Kabat et al., 1987). This amino acid substitution is an unusual one and, since position 94 is adjacent to CDR-3, it is at a surprisingly important position. For these reasons, the reshaped human 425  $V_H$  region is preferably designed based on the CDRs of mouse MAb 425 and FRs derived from the consensus sequence for human subgroup I FRs (as defined by Kabat et al., 1987). Positions 94 in FR-3 is made a serine as found in mouse MAb 425. At positions in the consensus sequence for human subgroup I FRs where no single amino acid are listed, the most commonly occurring amino acid at that position is selected. If there is no preferred amino acid at a particular position in the human consensus sequence, the amino acid that is found at that position in the sequence of mouse MAb 425  $V_H$  is selected. The resulting amino acid sequence comprises the first version (versions "a") of reshaped human 425  $V_H$  (Figure 3). All subsequent versions of reshaped human 425  $V_H$  are modifications of this first version.

A 454 bp DNA fragment coding for the reshaped human 425 V<sub>H</sub> region, as described above, is designed and synthesized (see examples and Figure 3). In addition to DNA sequences coding for the amino acids of reshaped human 425 V<sub>H</sub> region, this DNA  
5 fragment also contains sequences coding for a human leader sequence. The human leader sequence can be taken for example from antibody HG3 CL (Rechavi et al., 1983), a member of human V<sub>H</sub> subgroup I (Kabat et al., 1987). The synthetic DNA fragment also contains eukaryotic translation signals at the  
10 5'-end (Kozak, 1987), a donor splice site at the 3'-end (Breathnach et al., 1978), and HindIII and BamHI sites at the 5'- and 3'-ends, respectively, for subcloning into the HCMV expression vector.

15 A similar procedure is carried out for the design of the reshaped human 425 V<sub>L</sub> region. The FRs of mouse MAb 425 V<sub>L</sub> region are compared with the consensus sequences for all the subgroups of human V<sub>L</sub> regions (Kabat et al., 1987). Within the  
20 FRs, an approximately 71 % identity is found between mouse 425 V<sub>L</sub> and human kappa V<sub>L</sub> subgroup III, and an approximately 70 % identity with human kappa V<sub>L</sub> subgroup I. DNA coding for human FRs of human kappa V<sub>L</sub> subgroup I is already available from the reshaped human D1.3 V<sub>L</sub> region (EP 239 400, Winter)  
25 and reshaped human CAMPATH-1 (Reichmann et al., 1988). The design of the reshaped human V<sub>L</sub> regions in these two human antibodies is based on the structurally-solved human immunoglobulin REI protein (Epp et al., 1975). For these reasons, the human V<sub>L</sub> FRs from reshaped human D1.3 and CAMPATH-1H are  
30 also used in reshaped human 425 V<sub>L</sub>. A comparison of the FRs of mouse 425 V<sub>L</sub> region with FRs of other mouse antibodies from

similar subgroups reveal no significant differences in amino acid residues at functionally important positions. No changes in the human FRs are necessary therefore. The amino acid sequence of the reshaped human 425 V<sub>L</sub> region version "a" is shown in Figure 4.

To construct the reshaped human 425 V<sub>L</sub> region, three oligonucleotides are designed that contain internal DNA sequences coding for the three CDRs of mouse 425 V<sub>L</sub> region and also contain 12 bases at the 5'- and 3'-ends designed to hybridize to the DNA sequences coding for the human FRs in reshaped human D1.3 V<sub>L</sub> region (see oligonucleotides 7-9 in Table I). CDR-grafting is carried as described in the examples. After DNA sequencing of putative positive clones from the screening, the overall yield of the triple mutant is 5-15 %, preferably 9-10 %. A reshaped human 425 V<sub>L</sub> region containing no PCR errors is cloned as a HindIII-BamHI fragment into the light chain expression vector to create the plasmid HCMV-RV<sub>L</sub>a425-kappa (Figure 1).

The two expression vectors bearing the reshaped human 425 V<sub>L</sub> and V<sub>H</sub> regions are now co-transfected into appropriate cells (see above) to look for transient expression of a functional reshaped human 425 antibody. After approximately 72 h, the cell supernatants are harvested and assayed by ELISA for human IgG. Human IgG can be detected at levels ranging from 100-500 ng/ml, however, in the ELISA assay for antigen binding, binding to EGFR is surprisingly undetectable. When the cells are co-transfected with HCMV-RV<sub>L</sub>a425-kappa/HCMV-CV<sub>H</sub>425-

gamma-1, human IgG is produced and it binds to EGFR. However, when cells are co-transfected with HCMV-CV<sub>L</sub>425-kappa/HCMV-RV<sub>H</sub>a425-gamma-1, human IgG is produced but it does not bind to EGFR at detectable levels. From these unexpected results, it is clear that further inventive modifications in the FRs of reshaped human 425 V<sub>H</sub> are necessary in order to get a functional antigen-binding site.

Modifications in the FRs of reshaped human 425 V<sub>H</sub> region:

Further changes in the FRs of reshaped human 425 V<sub>H</sub> region are made based on a molecular model of the mouse 425 variable region domains. The CDR loops of the reshaped human V<sub>H</sub> region are examined to see how they fit into the canonical structures described by Chothia et al., 1989. As a result of this analysis, certain changes in the FRs are made. Other changes in the FRs are made based on a functional reshaped human anti-Tac antibody that was also designed based on human FRs from subgroup I (Queen et al., 1989). Surprisingly, the V<sub>H</sub> region of mouse anti-Tac antibody is approximately 79 % identical to the V<sub>H</sub> region of mouse 425 antibody. Now, according to the invention, a molecular model of the mouse 425 variable regions is made (Figure 5). The model is based on the structure of HyHEL-5, a structurally-solved antibody whose variable regions exhibit a high degree of homology to those of mouse 425 antibody. As a result of the above analysis, amino acid residues at positions 30, 48, 67, 68 and 71

in the reshaped human 425 V<sub>H</sub> region are changed to be identical to the amino acids occurring at those positions in mouse 425 V<sub>H</sub> region. To dissect the individual effects of these changes, a variety of combinations of these changes are constructed and tested according to the invention.

In total, 8 new versions of the reshaped human 425 V<sub>H</sub> region are constructed (see Figure 4). From the versions generated by the methods described in detail in the examples, other versions are made by recombining small DNA fragments from previous versions. Once all the desired versions are assembled preferably in pUC18, the reshaped human 425 V<sub>H</sub> regions are transferred as HindIII-BamHI fragments into the HCMV-V<sub>H</sub> expression vector thus generating versions "b" to "i" of plasmid HCMV-RV<sub>H</sub>425-gamma-1 (Figure 4).

Modifications in the FRs of reshaped human 425 V<sub>L</sub> region:

Although the corresponding cells co-transfected with vectors expressing the reshaped human 425 light chain, version "a", and chimeric 425 heavy chain do produce an antibody that bound to EGFR, the antibody with the reshaped human 425 light chain does not appear to bind as well as chimeric 425 antibody. Examination of the V<sub>L</sub> regions of mouse 425 and reshaped human 425 version "a" reveal that residue 71, which is part of the canonical structure for CDR-1 (L1), is not retained in version "a" (Chothia et al., 1989). The PCR-mutagenesis



method (Kamman et al., 1989) is preferably used to introduce a Phe to Tyr change at this position. The HindIII-BamHI fragment generated from this mutagenesis is introduced into the HCMV-V<sub>L</sub> expression vector to generate HCMV-RV<sub>L</sub>b425-kappa  
5 (Figure 4).

Analysis of the new versions of reshaped human 425 V<sub>H</sub> region:

The expression vectors containing reshaped human V<sub>H</sub> versions  
10 "a" to "i" are co-transfected into the above characterized cells with the expression vector containing reshaped human V<sub>L</sub> region version "a". After about 3 days, the cell supernatants are analyzed by ELISA for human IgG production. Levels of  
15 production vary between 50-500 ng/ml. The samples are then analyzed by ELISA for human IgG capable fo binding to EGFR. The different versions of reshaped human VH regions result in a wide variety of levels of antigen binding (Figure 6). In  
20 this ELISA assay for antigen binding, the various reshaped human 425 antibodies can be directly compared with chimeric 425 antibody, but no to mouse 425 antibody. This is because the antibody used to detect binding to antigen is an anti-human IgG antibody. The nine versions of reshaped human V<sub>H</sub>  
25 region can be grouped according to their ability to bind to EGFR. Reshaped human V<sub>H</sub> region version "g" and "i" provide the highest levels of binding, followed by version "c", "f", and "h", and then followed by version "b". In some experiments, version "e" gives low, but detectable, levels of binding. Versions "a" and "d" never give detectable levels of binding.

30

A competition binding assay is used to directly compare the reshaped human 425 antibodies containing versions "g" and "i" of  $V_H$ , and the chimeric 425 antibody, to mouse 425 antibody (Figure 7). Since the antibodies in the cell supernatants are not purified and are, therefore, quantitated by ELISA, the results from the competition-binding assay are regarded as giving relative levels of binding rather than an accurate quantitation of affinity. Competition binding assays with samples from four experiments in, for example, COS cells provide consistent results with respect to relative levels of binding to antigen. Chimeric 425 antibody compete well with the labelled mouse 425 antibody and give a percent inhibition of binding just slightly less than that obtained when unlabelled mouse 425 antibody is competed with labelled mouse 425 antibody (Figure 7, Panel A). Reshaped human antibody with  $V_{L\alpha}$  and  $V_{H\beta}$  is better than that with  $V_{L\alpha}$  and  $V_{H\delta}$  region (Figure 7, Panel B). Comparison of the plateau points of the binding curves indicates that the reshaped human antibody with  $V_{H\beta}$  competes with labelled mouse 425 antibody 60-80 % as well as the unlabelled mouse 425 antibody does in the same assay. When the results using samples from four independent experiments in, for example, COS or CHO cells were averaged, reshaped human antibody containing  $V_{L\alpha}$  and  $V_{H\beta}$  give a binding that is 60-80 % that of mouse 425 antibody.

Based on these results, it is possible to comment on the relative contributions of individual residues in the FRs make to antigen binding. The most significant single change in this study is the L71V change. Without this change, surprisingly, no binding to antigen is detectable (compare versions

"a" and "b" of V<sub>H</sub>). The R67K and V68A changes are, surprisingly, also important for binding (compare versions "b" and "c", and versions "i" and "h" of V<sub>H</sub>). While introduction of V48KI change alone, and V48I and S30T together, fail to produce significant antigen binding, changes at these positions do enhance antigen binding. The S30T change, surprisingly seems to have a greater effect than the V48I change (compare versions "g" and "i", and versions "f" and "i" of V<sub>H</sub>).

Analysis of the new version of reshaped human 425 V<sub>L</sub> region:

The expression vector containing the RV<sub>L</sub>b425 was co-transfected into appropriate preferably eukaryotic cells with the expression vector containing reshaped human V<sub>H</sub> region versions "b", "c" or "g". Cell supernatants are harvested and assayed for human IgG production and then for human IgG capable of binding to EGFR (Figure 8, Panel A). These results show that version "b" of reshaped human 425 V<sub>L</sub> region increases the binding to antigen. A competition binding assay is then carried out to compare reshaped human 425 antibodies with V<sub>L</sub>a plus V<sub>H</sub>g and V<sub>L</sub>b plus V<sub>H</sub>g to mouse 425 antibody. Reshaped human MAb 425 with version "b" of the V<sub>L</sub> region has a greater avidity for antigen. Thus, a F71Y change in the V<sub>L</sub> increases antigen binding. The reshaped human MAb 425 with V<sub>L</sub>b and V<sub>H</sub>g has an avidity for antigen 60-80 % of that of the murine MAb 425.

From other experiments, using a reshaped human antibody containing  $V_Lb$  plus  $V_{Hg}$  (Examples 10, 11) it can be seen, that the binding potency to EGFR is similar for chimeric, reshaped and murine antibodies.

5

The invention demonstrates that relatively conservative changes in the FR residues can strongly influence antigen-binding.

10

The molecular model of mouse 425 variable regions clearly shows this residue at position 30 in  $V_H$  to be on the surface of the molecule, in the vicinity of CDR-1. In fact, H1, as defined by Chothia and Lesk, 1987, extends from residues 26 to 32, thus encompassing the residue at position 30. When the residue at position 30 is changed from Ser to Thr in the

15 CAMPATH-1H antibody, it has no effect on antigen binding. When position 30 is changed from Ser to Thr in reshaped human  $V_H425$ , binding to antigen is improved. It appears that the amino acid at position 30 does play a role in antigen binding

20 in this particular antibody-antigen interaction. Since the S30T change only improves antigen binding slightly and since the change is not essential for antigen binding, the Thr at position 30 has only a weak interaction with the antigen.

25

The residue change at position 71 in  $V_H$  strongly influences antigen binding. This is surprising since the two residues tested at this position, Val and Leu, only differ by one methyl group. H2 of mouse 425 antibody is a member of H2, group 2 canonical structures as defined by Chothia et al.,

30 1989. HyHEL-5 has an H2 with an amino acid sequence similar to that of the H2 of mouse 425 antibody. In HyHEL-5, a Pro at

position 52A in CDR-2 packs into a cavity created by the small amino acid (Ala) at position 71 in the FRs. In the model of the mouse 425 variable regions, there is a similar interaction between Pro-52A and Val-71. Although in mouse 425 V<sub>H</sub> the Pro at position 52A is able to pack into the cavity created by Val at position 71, replacement of Val-71 with a Leu causes molecular clashing that could alter the conformation of the CDR-2 loop. For this reason, the V71L change in reshaped human VH425 re-creates the CDR-2-FR interaction as it occurs in mouse 425 V<sub>H</sub>. This, surprisingly, greatly improves the antigen-binding properties of the reshaped human 425 antibodies (compare reshaped human antibodies with versions "a" and "b" of V<sub>H</sub> in Figure 6).

The change at position 71 in V<sub>L</sub> probably affects CDR conformation because residue 71 is a member of the proposed canonical structure for L1 (CDR-1) (Chothia et al., 1989). Residue 29 in CDR-1 is a buried residue and has a contact with residue 71 in the FRs. In mouse 425 antibody, residue 71 in V<sub>L</sub> is Tyr. In the human FRs used for constructing the reshaped human V<sub>L</sub>s, it is a Phe. It appears that the hydroxyl group found in Tyr, but not in Phe, has a role in maintaining the correct conformation of CDR-1.

From the molecular model of the mouse 425 variable regions, it appears that Lys-66 forms a salt bridge with Asp-86. Introduction of larger Arg residue at position 66 would disrupt the structure. Ala-67 may interact with CDR-2 and simultaneously changing residues 66 and 67 to Arg and Val, as in V<sub>H</sub>a425, could have an adverse steric effect on CDR-2. The

residue at position 48 is known to be buried (Chothia and Lesk, 1987), and the model confirms this. Changing residue 48 from an Ile, as found in mouse 425 antibody, to a Val, as found in human V<sub>H</sub> regions of subgroup I, could affect antigen binding by generally disrupting the structure. The amino acid at position 48 is also close to CDR-2 and may have a subtle steric effect on the CDR-2 loop.

From the competition binding studies, the best reshaped human V<sub>L</sub> and V<sub>H</sub> regions are V<sub>L</sub>b and V<sub>H</sub>g. V<sub>H</sub>g has all 5 of the FR changes discussed above plus the change at position 94 that is included in the first version of reshaped human 425 V<sub>H</sub> region. The FRs in version "b" of reshaped human 425 V<sub>L</sub> region are 70 % identical to those in mouse 425 V<sub>L</sub> region. The FRs in version "g" of reshaped human 425 V<sub>H</sub> region are 80 % identical to those in mouse.

#### Therapeutic and diagnostic use of the antibodies:

The antibodies according to the invention can be administered to human patients for therapy or diagnosis according to known procedures. Typically the antibody, or antibody fragments, will be injected parenterally, preferably intraperitoneally. However, the monoclonal antibodies of the invention can also be administered intravenously.

Determination of appropriate titers of antibody to administer is well within the skill of the art. Generally, the dosage ranges for the administration of the monoclonal antibodies of the invention are those large enough to produce the desired tumor suppressing effect. The dosage should not be so large

as to cause adverse side effects, such as unwanted cross reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counter indications, immune tolerance or similar conditions. Dosage can vary from 0.1 mg/kg to 70 mg/kg, preferably 0.1 mg/kg to 500 mg/kg/dose, in one or more doses administrations daily, for one or several days.

Preparations for parenteral administration includes sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

The antibodies can be conjugated to a toxin such as ricin subunit A, diptheria toxin, or toxic enzyme. Alternatively it can be radiolabelled according to known methods in the art. However, the antibody of the present invention display excellent cytotoxicity, in the absence of toxin, in the presence of effector cells, i.e. human monocytes.

5 Solid tumors which can be detected and treated using the present methods include melanoma, glioma and carcinoma. Cancer cells which do not highly express EGFR-receptors can be induced to do so using lymphokine preparations. Also lymphokine preparations may cause a more homogenous expression of EGF-receptors among cells of a tumor, leading to more effective therapy.

10 Lymphokine preparations suitable for administration include interferon-gamma, tumor necrosis factor, and combinations thereof. These can be administered intravenously. Suitable dosages of lymphokine are 10,000 to 1,000,000 units/patient.

15 For diagnostic purposes the antibody can be conjugated to a radio-opaque dye or can be radiolabelled. A preferred labeling method is the Iodogen method (Fraker et al., 1978). Preferably the antibody will be administered as  $F(ab')_2$  fragments for diagnostic purposes. This provides superior results so that background subtraction is unnecessary.

20 Fragments can be prepared by known methods (e.g., Herlyn et al., 1983). Generally pepsin digestion is performed at acid pH and the fragments are separated from undigested IgG and heavy chain fragments by Protein A-Sepharose™ chromatography.

25 The reshaped human 425 antibodies according to the invention are less likely than either mouse or chimeric 425 antibodies to raise an immune response in humans. The avidity of the best version of reshaped human 425 antibody equals that of mouse or chimeric 425 antibody in the best embodiments of the invention. Binding studies show that the potency to compete

30 with EGF for binding to EGFR under optimized



conditions is the same for chimeric, reshaped and murine antibodies. Moreover, the reshaped human 425 antibodies are more efficacious, when used therapeutically in humans, than either the mouse or chimeric 425 antibodies. Due to the great  
5 reduction in immunogenicity, the reshaped human 425 antibody has a longer half-life in humans and is the least likely to raise any adverse immune response in the human patient.

The results of the defined MAb 425 show that humanized mono-  
10 clonal antibodies having an artificial consensus sequence do not effect a remarkable minimum response. Further advantages are described above in the paragraph: Summary of the Invention.

15 Therefore, the value of the new antibodies of the invention for therapeutic and diagnostic purposes is extraordinarily high.

References cited in the specification:

- 20 Amit et al. (1986), Science 233, 747  
Aviv et al. (1972), Proc. Nat. Acad. Sci. USA 69, 1408  
Bernstein et al. (1977), J. Mol. Bio. 112, 525  
Breathnach et al. (1978), Proc. Natl. Acad. Sci USA 75, 4853  
25 Brooks et al. (1983), J. Comp. Chem 4, 187  
Brüggemann et al. (1987), J. Exp. Med. 166, 1351  
Carter et al. (1985), Oligonucleotide Sitedirected Mutagenesis in M 13, an Experimental Approach Manual, Anglian Biotechnology Ltd. Colchester  
30 Chirgwin et al. (1979), Biochemistry 18, 5294  
Chothia et al. (1987), J. Mol. Biol. 196, 901

- Chothia et al. (1989), Nature 342, 877
- Co et al. (1991), Proc. Natl. Acad. Sci. USA 88, 2869
- Cohen (1982), J. Biol. Chem. 258, 1523
- Downward et al. (1984), Nature 307, 521
- 5 Epp et al. (1975), Biochemistry 14, 4943
- Epp et al. (1983), Eur. J. Biochem. 133, 51
- Fraker et al. (1978), Biochem. Biophys. Res. Commun. 80, 849
- Gillis et al. (1990), Hum. Antibod. Hybridomas 1, 47
- Giorgi et al. (1983), Transplant. Proc. 15, 639
- 10 Gorman et al. (1991), Proc. Natl. Acad. Sci. USA 88, 4181
- Gubler et al. (1983), Gene 25, 263
- Hale et al. (1988), Lancet, ii, 1394
- Herlyn et al. (1983), Cancer Res. 43, 2731
- Hoggenboom et al. (1990), J. Immunol. 144, 3211
- 15 Jaffers et al. (1986), Transplantation 41, 572
- Jones et al. (1986), Nature 321, 14
- Kaariten et al. (1983), J. Immunol. 130, 937
- Kabat et al. (1987), Sequences of Proteins of Immunological Interest. US Dept. Health and Human Services, US Government
- 20 Printing Offices
- Kammann et al. (1989), Nucleic Acids Res. 17, 5404
- Koprowski et al. (1985), Somatic Cell and Mol. Genetics 11, 297
- Kozak (1987), J. Mol. Bio. 196, 947
- 25 Levy et al. (1987), Gene 54, 167
- Liu et al. (1987), Proc. Natl. Acad. Sci. USA 84, 3439
- LoBuglio et al. (1989), Proc. Natl. Acad. Sci. USA 86, 4220
- Maeda et al. (1991), Hum. Antibod. Hybridomas 2, 124
- Martin (1990), D. Phil. thesis, Oxford University
- 30 Martin et al. (1989), Proc. Natl. Acad. Sci. USA 86, 9268
- Mathieson et al. (1990), N. Eng. J. Med. 323, 250
- Murthy et al. (1987), Arch. Biochem. Biophys. 252, 549
- Nakamaye et al. (1986), Nucleic Res. 14, 9679

- Padlan et al. (1989), Proc. Natl. Acad. Sci. USA 86, 5938
- Panka et al. (1988), Proc. Natl. Acad. Sci. USA 85, 3080
- Queen et al. (1989), Proc. Natl. Acad. Sci. USA 86, 10029
- Rabbitts et al. (1984), Curr. Top. Microbiol. Immunol. 113,  
5 166
- Rechavi et al. (1983), Proc. Natl. Acad. Sci. USA 80, 855
- Reichmann et al. (1988), Nature 322, 21
- Rodeck et al. (1987), Cancer Res. 47, 3692
- Sayers et al. (1988), Nucleic Acid Res. 16, 791
- 10 Schreiber (1983), J. Biol. Chem. 258, 846
- Sheriff et al. (1987), Proc. Natl. Acad. Sci. USA 84, 8075
- Show et al. (1986), Proteins 1, 267
- Suh et al. (1986), Proteins 1, 74
- Sun et al. (1987), Proc. Natl. Acad. Sci. USA 84, 214
- 15 Sutcliffe (1988), Ph. D. thesis, London University
- Takahashi et al. (1987), Cancer Res. 47, 3847
- Takahashi et al. (1982), Cell 29, 671
- Taylor et al. (1985a), Nucleic Acids Res. 13, 8749
- Taylor et al. (1985b), Nucleic Acids Res. 13, 8764
- 20 Tempest et al. (1991), Biol. Technology 9, 266
- Ulrich et al. (1984), Nature 309, 418
- Verhoeyen et al. (1988), Science 239, 18
- Verhoeyen et al. (1991), In Epenetos, A.A. (ed.), Monoclonal  
Antibodies: Applications in Clinical Oncology, Chapman and  
25 Hall, London, pp. 37
- Ward et al. (1989), Nature 341, 544
- Whittle et al. (1987), Protein Eng. 1, 499
- Williams et al. (1990), Tibtech 8, 256

**Example 1**Molecular cloning sequencing:

5 Total RNA was isolated from cell line W425-15 (ACCT HB 9629) which produces MAb 425. Approximately  $9.6 \times 10^7$  cells were used to produce total RNA using the guanidinium-CsCl method (Chirgwin et al., 1979). Supernatants from the cells used for total RNA isolation were assayed by ELISA to ensure that the  
10 cells were producing the correct MAb in high amounts. Poly(A<sup>+</sup>) RNA was prepared (Aviv and Leder, 1972). Double-stranded cDNA was synthesized essentially according to the methods of Gubler and Hoffman (1983) except that primers homologous to the 5'-regions of the mouse kappa and gamma-2a immunoglobulin  
15 constant regions were used to prime first-strand synthesis (Levy et al., 1987). The design of the light chain primer was a 26-mer (oligonucleotide 1, Table I) which was designed based on published data (Levy et al., 1987; Kaariten et al., 1983). The design of the heavy chain primer was a 25-mer  
20 (oligonucleotide 2, Table I) and designed based on published data (Kaariten et al., 1983; Kabat et al., 1987). Primers were designed and synthesized on an Applied Biosystems 380B DNA Synthesizer and purified on urea-acrylamide gels. After second-strand synthesis, the blunt-ended cDNAs were cloned  
25 into SmaI-digested pUC18 (commercially available) and transformed into competent E. coli cells, e.g. DH5-alpha (commercially available). Colonies were gridded onto agar plates and screened by hybridization using <sup>32</sup>P-labelled first-strand synthesis primers (Carter et al., 1985). Sequencing of double-stranded plasmid DNA was carried out using Sequenase  
30 (United States Biochemical Corporation).

**Example 2**Construction of chimeric genes:

5 For each variable region, a front 5' and back 3' polymerase chain reaction (PCR) primer was synthesized (oligonucleotides 3-6, Table I). PCR reactions were set up using 1 ng of pUC18 plasmid DNA containing the cloned cDNA, front and back PCR primers at a final concentration of 1  $\mu$ M each, 200  $\mu$ M of each  
10 dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, and 0.01 % gelatin (w/v). Amplitaq DNA polymerase (Perkin Elmer Cetus) was added at 2.5 units per assay. After an initial melt at 94 °C for 1.5 min, 25 cycles of amplification were performed at 94 °C for 1 min, 45 °C for 1 min, and 72 °C for  
15 3 min. A final extension step at 72 °C was carried out for 10 min. PCR reactions were phenol/chloroform extracted twice and ethanol precipitated before digesting with HindIII and BamHI. The PCR fragment coding for the V<sub>L</sub> or V<sub>H</sub> region was then cloned into an expression vector. This vector contains  
20 the HCMV (human cytomegalovirus) enhancer and promoter, the bacterial neo gene, and the SV40 origin of replication. A 2.0 Kb BamHI fragment of genomic DNA coding for the human gamma-1 constant region (Takahashi et al., 1982) was inserted in the correct orientation downstream of the V<sub>H</sub> region fragment  
25 (see HCMV-CV<sub>H</sub>425-gamma-1 in Figure 1). This vector was later adapted by removing the BamHI site at the 3'-end of the constant region fragment thus allowing variable regions to be directly inserted into the heavy chain expression vector as HindIII-BamHI fragments (Maeda et al., 1991). The fragment  
30 coding for the V<sub>L</sub> region was inserted into a similar HCMV

expression vector in this case containing a BamHI fragment of genomic DNA, approximately 2.6 Kb in size, coding for the human kappa constant region and containing a splice acceptor site and a poly(A<sup>+</sup>) (Rabbitts et al., 1984) (see HCMV-CV<sub>L</sub>-425-kappa in Figure 1).

### Example 3

#### Molecular modelling of MAb 425 V<sub>L</sub> and V<sub>H</sub>:

10

A molecular model of the variable regions of murine MAb 425 was built on the solved structure of the highly homologous anti-lysozyme antibody, HyHEL-5 (Sheriff et al., 1987). The variable regions of MAb 425 and HyHEL-5 have about 90 % homology.

15

The model was built on a Silicon Graphics Iris 4D workstation running UNIX and using the molecular modeling package "QUANTA" (Polygen Corp.). Identical residues in the framework were retained; non-identical residues were substituted using the maximum overlap (Snow and Amzel, 1986) incorporated into QUANTA's protein modeling facility. The main chain conformation of the three N-terminal residues in the heavy chain were substituted from a homologous antibody structure (HyHEL-10 (Padlan et al., 1989)) since their temperature factors were abnormally high (greater than the mean plus three standard deviations from the backbone temperature factors) and since they influence the packing of V<sub>H</sub> CDR-3 (H3) (Martin, 1990).

20

25

30

The CDR-1 (L1) and CDR-2 (L2) sequences of the  $V_L$  region and the CDR-1 (H1) and CDR-2 (H2) sequences of the  $V_H$  region from MAb 425 corresponded to canonical forms postulated by Chothia et al. (1989). The main chain torsion angles of these loops were kept as in HyHEL-5. The CDR-3 (L3) sequence of the  $V_L$  region and the CDR-3 (H3) of the  $V_H$  region from MAb 425 did not correspond to canonical structures and, therefore, were modeled in a different way. The computer program of Martin et al. (1989) was used to extract loops from the Brookhaven Databank (Bernstein et al., 1977). The loops were then sorted based on sequence similarity, energy, and structure-determining residues (Sutcliffe, 1988). The top-ranked loops were inspected on the graphics and the best selected by eye. H3 was modeled on bovine glutathione peroxidase (Epp et al., 1983) in the region of residues 92-103. L3 was modelled on the murine IgA (J539) Fab fragment (Suh et al., 1986) in the region of residues 88-96 of the light chain.

The model was subjected to steepest descents and conjugate gradients energy minimization using the CHARm potential (Brooks et al., 1983) as implemented in QUANTA in order to relieve unfavorable atomic contacts and to optimize Van der Waals and electrostatic interactions.

**Example 4**Construction of humanized antibody genes:

5     The construction of the first version of the reshaped human  
425 light chain was carried out using a CDR-grafting approach  
similar to that described by Reichmann et al. (1988) and  
Verhoeyen et al. (1988). Single-stranded template DNA was  
prepared from a M13mp18 vector (commercially available)  
10    containing a HindIII-BamHI fragment coding for the human  
anti-lysozyme V<sub>L</sub> region (EP 239 400, G. Winter). The FRs of  
this light chain are derived from the crystallographically-  
solved protein REI. Three oligonucleotides were designed  
which consisted of DNA sequences coding for each of the mouse  
15    MAb 425 light chain CDRs flanked on each end by 12 bases of  
DNA complementary to the DNA sequences coding for the adja-  
cent FRs of human REI (oligonucleotides 7-9 in Table I).  
Oligonucleotides were synthesized and purified as before. All  
three oligonucleotides were phosphorylated and used simulta-  
20    neously in an oligonucleotide-directed in vitro mutagenesis  
system based on the methods of Eckstein and coworkers (Taylor  
et al., 1985; Nakamaye and Eckstein, 1986; and Sayers et al.,  
1988). The manufacturer's instructions were followed through  
the exonuclease III digestion step. The reaction was then  
25    phenol/chloroform extracted, ethanol precipitated, and resus-  
pended in 100 µl of TE. A volume of 10 µl was used as tem-  
plate DNA in a 100 µl PCR amplification reaction containing  
M13 universal primer and reverse sequencing primer to a final  
concentration of 0.2 µM each. Buffer and thermocycling condi-  
30    tions were as described in Example 2 with the exception of  
using a 55 °C annealing temperature. The PCR reaction was  
phenol/chloroform extracted twice and ethanol precipitated



before digestion with HindIII and BamHI and subcloning into pUC18. Putative positive clones were identified by hybridization to <sup>32</sup>P-labelled mutagenic primers (Carter et al., 1987). Clones were confirmed as positive by sequencing. A V<sub>L</sub> region  
5 containing all three grafted CDRs was cloned as a HindIII-BamHI fragment into the V<sub>L</sub> expression vector to create the plasmid HCMV-RV<sub>L</sub>a425-kappa.

Version "b" of the reshaped V<sub>L</sub> was constructed using the PCR  
10 mutagenesis method of Kammann et al. (1989), with minor modifications. The template DNA was the RV<sub>L</sub>a subcloned into pUC18. The first PCR reaction was set up in a total volume of 50 µl and contained 1 ng template, M13 reverse sequencing  
15 primer and primer 10 (Table I) at a final concentrations of 1 µM, 200 µM dNTPs, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl, and 0.01 % (w/v) gelatin. Amplitaq DNA polymerase was added at a concentration of 1 unit per assay. The reaction was set up in triplicate. After melting at 94 °C for 1.5 min,  
20 the reactions were cycled at 1 min 94 °C, 1 min 37 °C, and 2 min 72 °C for 40 cycles, followed by an extension at 72 °C for 10 min. The reactions were pooled, phenol/chloroform extracted and ethanol precipitated before isolating the PCR  
25 product from a TAE agarose gel. A tenth of the first PCR reaction was then used as one of the primers in the second PCR reaction. The second reaction was as the first except the first reaction product and 20 pmol of M13 universal primer were used. Cycling was as described by Kammann et al. (1989).  
The HindIII-BamHI fragment was cloned into pUC18 and  
30 sequenced. A DNA fragment bearing the desired change was subcloned into the V<sub>L</sub> expression plasmid to create plasmid HCMV-RV<sub>L</sub>b425-kappa.

The first version of the reshaped human  $V_H$  region of 425 was chemically synthesized. A DNA sequence was designed coding for the required amino acid sequence and containing the necessary flanking DNA sequences (see above). Codon usage was optimized for mammalian cells with useful restriction enzyme sites engineered into the DNA sequences coding for FRs. The 454 bp was synthesized and subcloned into pUC18 as an EcoRI-HindIII fragment. A HindIII-BamHI fragment coding for the reshaped humanized 425 heavy chain was then transferred into the  $V_H$  expression vector, to produce the plasmid HCMV-RV<sub>H</sub>a-425-gamma-1.

Eight other versions of the reshaped humanized heavy chains were constructed by a variety of methods. The HindIII-BamHI fragment coding for the version "a" of the heavy chain was transferred to M13mp18 and single-stranded DNA prepared. Using oligonucleotides 11-13 (Table I), PCR-adapted M13 mutagenesis, as described above, was used to generate DNA coding for reshaped human 425  $V_H$  regions versions "d", "e", "f" and "g" in pUC18. These versions were subcloned into the heavy chain expression vector as HindIII-BamHI fragments to create plasmids HCMV-RV<sub>H</sub>d425-gamma-1, HCMV-RV<sub>H</sub>e425-gamma-1, HCMV-RV<sub>H</sub>f425-gamma-1, and HCMV-RV<sub>H</sub>g425-gamma-1.

Reshaped human 425  $V_H$  regions versions "b" and "c" were generated using the PCR mutagenesis method of Kammann et al. (1989) as described above. The template DNA was reshaped human 425  $V_H$  region version "a" subcloned into pUC18, and the mutagenic primer used in the first PCR reaction was either

primer 13 or 14 (Table I). After mutagenesis and sequencing, sequences bearing the desired changes were subcloned into the heavy chain expression plasmid to create plasmids. HCMV-RV<sub>h</sub>b425-gamma-1 and HCMV-RV<sub>h</sub>c425-gamma-1.

5

Reshaped heavy chain versions "h" and "i" were constructed from the pUC-based clones of existing versions. A 0.2 Kb HindIII-XhoI fragment from version "e" was ligated to a 2.8 Kb XhoI-HindIII fragment from either version "b" or "c" producing the new versions "h" and "i", respectively. The HindIII-BamHI fragments coding for these versions were subcloned into the heavy chain expression vector to produce the HCMV-RV<sub>h</sub>h425-gamma-1 and HCMV-RV<sub>h</sub>i425-gamma-1.

10

15

#### **Example 5**

##### Transfection of DNA into COS cells:

20

COS cells were electroporated with 10 µg each of the expression vectors bearing the genes coding for the heavy and light chains. Briefly, 10 µg of each plasmid was added to a 0.8 ml aliquot of a  $1 \times 10^7$  cells/ml suspension of COS cells in PBS. A Bio-Rad™ Gene Pulser was used to deliver a pulse of 1900 V, with a capacitance of 25 µF. The cells were left to recover at room temperature for 10 min before plating into 8 ml DMEM containing 10 % fetal calf serum. After 72 h incubation, the media was collected, centrifuged to remove cellular debris, and stored under sterile conditions at 4 °C for short periods, or at -20 °C for longer periods, prior to analysis by ELISA.

25

30

**Example 6**

The transfection of DNA into CHO cells was done according to Example 5.

5

**Example 7**

Quantification of IgG production and detection of antigen binding:

10

Human IgG present in COS cell supernatants was detected by ELISA: In the ELISA assay for human IgG, 96-well plates were coated with goat anti-human IgG (whole molecule) and human IgG in the samples that bound to the plates was detected using alkaline phosphatase-conjugated goat anti-human IgG (gamma-chain specific). Purchasable purified human IgG was used as a standard. Binding to the antigen recognized by MAb 425 was determined in a second ELISA. Plates were coated with an EGFR protein preparation (obtainable, for example, according to Rodeck et al., 1980) and antibodies binding to EGFR were detected using either an anti-human IgG (gamma-chain specific) peroxidase conjugate (for chimeric and reshaped human antibodies) or an anti-mouse IgG (whole molecule) peroxidase conjugate (for the mouse MAb 425 antibody) (both conjugates supplied by Sigma). Purified murine MAb 425 was used as a standard.

30

**Example 8**Competition binding assay:

- 5 Murine MAb 425 was biotinylated using a correspondingly purchasable kit. ELISA plates were coated with an optimal dilution of the EGFR protein. Dilutions of the COS cell supernatants, in a volume of 50  $\mu$ l, were mixed with 50  $\mu$ l of the biotinylated murine MAb 425 (estimated by ELISA to be  
10 1.75  $\mu$ g/ml). Each COS cell supernatant was tested in duplicate. Plates were incubated at room temperature, overnight. Bound biotinylated murine MAb 425 was detected by the addition of a purchasable streptavidin horseradish peroxidase complex. A control with no competitor present allowed a value  
15 of percentage of inhibition or blocking to be calculated for each COS cell supernatant as follows:

$$100 - [ (OD_{450} \text{ of sample} / OD_{450} \text{ of control}) \times 100 ]$$

20 **Example 9**

- Different probes of murine, reshaped and chimeric MAb 425 were analyzed by SDS-Polyacrylamide-Gelspaceelectrophoresis (SDS-PAGE) according to Laemmli et al. 2.5  $\mu$ g of each sample  
25 were applied to each well under non-reducing as well as under reducing conditions. Protein was visualized by Coomassie staining. Fig. 9 (A) shows that the samples have similar purity.

- 30 MW range of the antibodies: 180,000 - 200,000.

**Example 10**

Reshaped MAb 425 was purified by gelspacefiltration on Super-  
ose 12™ (Pharmacia Corp. Sweden) according to standard meth-  
ods. The antibody was eluted with PBS (pH 7.4, 0.8 M NaCl)  
5 (0.1 M). A single peak (at 5 min) can be obtained (Fig. 9  
(B)).

**Example 11**

10 Biotin-labelled MAb 425 was used to compete with unlabelled  
MAb 425 or derivates for binding to EGFR. Biotin-labelling  
occurred according to standard methods. EGFR was solubilized  
from A431 membranes by standard methods. A431 cells were  
15 commercially purchased. Detection was done after incubation  
with POD-conjugated streptavidin and substrate. From this  
data inhibition curves were constructed (Fig. 10). The curves  
show that the binding of the various antibodies are compara-  
ble.

20

**Example 12**

Different probes of purified murine, chimeric and reshaped  
MAbs 425 were tested for their potency to compete with EGF  
25 regarding their binding to EGFR. The test was performed by  
competing <sup>125</sup>I-labelled EGF (Amersham Corp., GB) and various  
antibodies for binding to EGF-receptor positive membranes  
(A431). The test system is based on SPA technology (Amer-  
sham). The competition curves of the murine and the reshaped  
30 antibodies (3 probes) are nearly identical (Fig. 11).

5

Patent Claims

- 10 1. Humanized monoclonal antibody comprising antigen binding sites (CDRs) of non-human origin, and the FRs of variable region and constant regions of light and heavy chains of human origin, characterized in that at least the FRs of the variable region of the heavy chain comprise a modified consensus sequence of different variable regions of
- 15 a distinct class or subgroup of a human immunoglobulin.
2. Humanized monoclonal antibody according to Claim 1, wherein the FRs of the consensus sequence has a homology of at least 70 % compared with the amino acid sequence of
- 20 the FRs of the variable regions of the non-human antibody from which the antigen binding sites originate.
3. Humanized monoclonal antibody according to Claim 1 or 2, having the following properties:
- 25 (a) binds to human EGF-receptors;
- (b) inhibits binding of EGF to EGF-receptor;
- (c) inhibits the EGF-dependent tyrosine kinase activity of EGF-receptor;
- 30 (d) inhibits the growth of EGF-sensitive cells.

62

4. Humanized monoclonal antibody according to Claim 3, wherein the hypervariable regions of the antigen binding sites comprise the following amino acid sequences:

5        **light chain**

CDR-1    -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-

CDR-2    -Asp-Thr-Ser-Asn-Leu-Ala-Ser-

CDR-3    -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

10

**heavy chain**

CDR-1    -Ser-His-Trp-Met-His-

CDR-2    -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-

15        Glu-Lys-Phe-Lys-Ser-

CDR-3    -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-

5. Humanized monoclonal antibody according to Claim 4, wherein the FRs of the variable region which is not related to the antigen binding sites comprise the following amino acid sequence:
- 20

**light chain**

25        FR-1    -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-

FR-2    -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-Ile-Tyr-

30



63

FR-3     -Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-  
           Thr-Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-  
           Leu-Gln-Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-  
 FR-4     -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

5

**heavy chain**

FR-1     -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-  
           Lys-Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-  
 10        Ser-Gly-Tyr-Thr-Phe-Thr (Ser) -  
 FR-2     -Trp-Val-Arg (His) -Gln-Ala (Lys, His) -Pro (Val) -Gly-  
           Gln-Gly-Leu-Glu-Trp-Ile (Val, Leu) -Gly-  
 FR-3     -Lys (Arg, His) -Ala (Val-Pro-Gly) -Thr-Met-Thr-  
           Val (Ala, Pro, Gly) -Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-  
 15        Met-Glu (Asn) -Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-  
           Ala-Val-Tyr-Tyr-Cys-Ala-Ser-  
 FR-4     -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser-,

20        and wherein the amino acids listed in the brackets are  
           alternatives.

6. Humanized monoclonal antibody according to Claim 4 or 5,  
 wherein the constant regions of the heavy chain comprise  
 the amino acid sequence of a gamma-1 chain, and the  
 25        constant regions of the light chain comprise the amino  
           acid sequence of a kappa chain of a human immunoglobulin.
7. Humanized monoclonal antibody according to one of the  
 Claims 3 to 6, comprising a derivate of an amino acid  
 30        sequence modified by amino acid deletion, substitution,  
           addition or inversion within the variable and constant  
           regions wherein the biological function of specific  
           binding to the antigen is preserved.

64

8. Expression vector, suitable for transformation of host cells, characterized in that it comprises a DNA sequence coding for the variable and/or constant regions of the light and/or heavy chains of a humanized antibody according to Claims 1 to 7.

9. Expression vector according to Claim 8, wherein the DNA sequences are coding for an antibody protein according to one of the antibodies of Claims 3 to 7.

10

10. Expression vector having the designation pRVL425, deposited at DSM under Accession No. DSM 6340.

15

11. Expression vector having the designation pRVH425, deposited at DSM under Accession No. DSM 6339.

20

12. Humanized or chimeric monoclonal antibody, comprising hypervariable regions (CDRs) of antigen binding sites of murine origin and the FRs of variable regions of human or murine origin and constant regions of light and heavy chains of human origin, characterized in that the hypervariable regions comprise the following amino acid sequences,

25

**light chain**

CDR-1 -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-

CDR-2 -Asp-Thr-Ser-Asn-Leu-Ala-Ser-

CDR-3 -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

30

65

**heavy chain**

CDR-1 -Ser-His-Trp-Met-His-

CDR-2 -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-

5 Glu-Lys-Phe-Lys-Ser-

CDR-3 -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-

Tyr-,

10 and wherein the constant regions of the heavy chain  
comprise the amino acid sequence of a gamma-1 chain, and  
the constant regions of the light chain comprise the  
amino acid sequence of a kappa chain of a human immuno-  
globulin.

- 15 13. Humanized monoclonal antibody according to Claim 12,  
wherein the FRs of the variable region which is not  
related to the antigen binding sites, are of human origin  
and comprise the following amino acid sequence,

20 **light chain**FR-1 -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-  
Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-25 FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-  
Leu-Ile-Tyr-FR-3 Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-  
Thr-Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-  
Leu-Gln-Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-

FR-4 -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

30

66

**heavy chain**

- FR-1 -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-  
Lys-Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-  
5 Ser-Gly-Tyr-Thr-Phe-Thr (Ser) -
- FR-2 -Trp-Val-Arg (His) -Gln-Ala (Lys, His) -Pro (Val) -Gly-  
Gln-Gly-Leu-Glu-Trp-Ile (Val, Leu) -Gly-
- FR-3 -Lys (Arg, His) -Ala (Val, Pro, Gly) -Thr-Met-Thr-  
Val (Ala, Pro, Gly) -Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-  
10 Met-Glu (Asn) -Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-  
Ala-Val-Tyr-Tyr-Cys-Ala-Ser-
- FR-4 -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser-

14. Chimeric monoclonal antibody according to Claim 12,  
15 wherein the FRs of the variable region which is not  
related to the antigen binding site, are of murine origin  
and comprise the following amino acid sequences:

**light chain**

- 20 FR-1 -Gln-Ile-Val-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Met-Ser-  
Ala-Ser-Pro-Gly-Glu-Lys-Val-Thr-Met-Thr-Cys-
- FR-2 -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Ser-Ser-Pro-Arg-Leu-  
Leu-Ile-Tyr-
- 25 FR-3 -Gly-Val-Pro-Val-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-  
Thr-Ser-Tyr-Ser-Leu-Thr-Ile-Ser-Arg-Met-Glu-Ala-  
Glu-Asp-Ala-Ala-Thr-Tyr-Tyr-Cys-
- FR-4 -Phe-Gly-Ser-Gly-Thr-Lys-Leu-Glu-Ile-Lys-

30

67

**heavy chain**

- FR-1     -Gln-Val-Gln-Leu-Gln-Gln-Pro-Gly-Ala-Glu-Leu-Val-  
           Lys-Pro-Gly-Ala-Ser-Val-Lys-Leu-Ser-Cys-Lys-Ala-  
 5           Ser-Gly-Tyr-Thr-Phe-Thr-
- FR-2     -Trp-Val-Lys-Gln-Arg-Ala-Gly-Gln-Gly-Leu-Glu-Trp-  
           Ile-Gly-
- FR-3     -Lys-Ala-Thr-Leu-Thr-Val-Asp-Lys-Ser-Ser-Ser-Thr-  
           Ala-Tyr-Met-Gln-Leu-Ser-Ser-Leu-Thr-Ser-Glu-Asp-  
 10          Ser-Ala-Val-Tyr-Tyr-Cys-Ala-Ser-
- FR-4     -Trp-Gly-Gln-Gly-Thr-Thr-Leu-Thr-Val-Ser-Ser-
15. Expression vector, suitable for transformation of host  
 15        cells, characterized in that it comprises DNA sequences  
           coding for the variable and constant regions of the light  
           and/or heavy chains of a humanized monoclonal antibody  
           according to Claim 12 or 13, or of a chimeric monoclonal  
           antibody according to Claim 12 or 14.
- 20       16. Expression vector having the designation pCVL425, depos-  
           ited at DSM under Accession No. DSM 6338.
17. Expression vector having the designation pCVH425, depos-  
           ited at DSM under Accession No. DSM 6337.
- 25       18. Process for the preparation of a humanized monoclonal  
           antibody, comprising hypervariable regions (CDRs) of  
           antigen binding sites of non-human origin, and FRs of the  
           variable regions and constant regions of the light and  
 30        heavy chains of human origin by cultivating transformed  
           host cells in a culture medium and purification and  
           isolation the expressed antibody proteins, characterized  
           in

- 5 (a) synthesizing or partially synthesizing or isolating  
an oligonucleotide sequence which codes for an amino  
acid consensus sequence of different FRs of the vari-  
able regions (FR-1 to FR-4) of a heavy chain of a  
class or a subgroup of a human immunoglobulin,  
wherein the used consensus sequence has a homology of  
at least 70 % compared with the amino acid sequence  
of the FRs of the variable regions of the non-human  
antibody from which the antigen binding sites origi-  
10 nate, and wherein the consensus sequence is modified  
by alterations of maximum 10 % of the amino acids in  
order to preserve the binding capability of the anti-  
gen to the hypervariable regions;
- 15 (b) synthesizing or partially synthesizing or isolating  
an oligonucleotide sequence which codes for an amino  
acid consensus sequence under the conditions given in  
(a) of different FRs of the variable regions (FR-1 to  
FR-4) of a light chain of a class or a subgroup of a  
20 human immunoglobulin, or, alternatively, which codes  
for a corresponding natural occurring amino acid  
sequence;
- 25 (c) in each case synthesizing or partially synthesizing  
or isolating an oligonucleotide sequence which codes  
for the amino acid sequence of the hypervariable  
regions (CDRs) of the light and heavy chain corre-  
sponding to the hypervariable regions of the basic  
non-human antibody;

(d) in each case synthesizing or partially synthesizing or isolating an oligonucleotide sequence which codes for the amino acid sequence of the constant regions of the light and heavy chain of a human immunoglobulin;

5

(e) constructing one or several expression vectors comprising in each case at least a promoter, a replication origin and the coding DNA sequences according to (a) to (d), wherein the DNA sequences coding for the light and heavy chains can be present together in one or, alternatively, in two or more different vectors,

10

and finally,

15

(f) transforming the host cells with one or more of the expression vectors according to (e).

19. Process according to Claim 18, wherein DNA sequences are used coding for the following amino acid sequences which represent the hypervariable regions (CDRs):

20

**light chain**

25

CDR-1 -Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr-

CDR-2 -Asp-Thr-Ser-Asn-Leu-Ala-Ser-

CDR-3 -Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr-

30

70

**heavy chain**

CDR-1    -Ser-His-Trp-Met-His-  
CDR-2    -Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-Tyr-Asn-  
5            Glu-Lys-Phe-Lys-Ser-  
CDR-3    -Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr-

20. Process according to Claim 18 or 19, wherein DNA  
sequences are used coding for the following amino acid  
10 sequences which represent the FRs of the variable  
regions:

**light chain**

15        FR-1    -Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-  
          Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-  
          FR-2    -Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-  
                  Leu-Ile-Tyr-  
          FR-3    -Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-  
20            Thr-Asp-Tyr (Phe, Trp, His) -Thr-Phe-Thr-Ile-Ser-Ser-  
                  Leu-Gln-Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys-  
          FR-4    -Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-

**heavy chain**

25        FR-1    -Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-Val-Lys-  
                  Lys-Pro-Gly-Ala-Ser-Val-Lys-Val-Ser-Cys-Lys-Ala-  
                  Ser-Gly-Tyr-Thr-Phe-Thr (Ser) -  
          FR-2    -Trp-Val-Arg- (His) -Gln-Ala (Lys, His) -Pro (Val) -Gly-  
30            Gln-Gly-Leu-Glu-Trp-Ile (Val, Leu) -Gly-



71

FR-3     -Lys (Arg, His) -Ala (Val, Pro, Gly) -Thr-Met-Thr-  
Val (Ala, Pro, Gly) -Asp-Thr-Ser-Thr-Asn-Thr-Ala-Tyr-  
Met-Glu (Asn) -Leu-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-  
Ala-Val-Tyr-Tyr-Cys-Ala-Ser-

5         FR-4     -Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser

21. Process for the preparation of a chimeric monoclonal  
antibody having the biological function of binding to  
epitopes of the EGF-receptor, comprising hypervariable  
10       regions (CDRs) of antigen binding sites and FRs of the  
variable regions of murine origin           and FRs of the  
variable regions of murine origin and constant regions of  
the light and heavy chains of human origin by cultivating  
transformed host cells in a culture medium and purifica-  
15       tion and isolation the expressed antibody proteins,  
characterized in that the host cells are transformed with  
expression vectors according to one of the expression  
vectors of Claims 15 to 17.

20       22. Pharmaceutical composition comprising a humanized mono-  
clonal antibody according to one of the antibodies of  
Claims 1 to 7 or 12 to 13.

23. Pharmaceutical composition comprising a chimeric mono-  
25       clonal antibody according to one of the antibodies of  
Claim 12 or 14.

24. Use of humanized or chimeric antibody according to one of  
the antibodies of Claims 3 to 7 or 12 to 14 for the  
30       manufacture of a drug directed to tumors.

72

25. Use of humanized or chimeric antibody according to one of the antibodies of Claims 3 to 7 or 12 to 14 for diagnostic locating and assessing tumor growth.

5 26. Purified humanized and chimeric monoclonal antibody which derives from murine MAb 425.

10


15

20

25

30

FIG.1



2/12  
FIG. 2

## Panel A:

5'-----CGAGCTCGG-CTGAGCACACAGGACCTCACCATG GGT TGG AGC TAT 45  
 pUC18----->-3'-GACTCGTGTGTCTGGAGTGGTACCCA-----5'  
 5'-CTCCAAGCTTGACCTCACCATGG-3'  
 HindIII Met Gly Trp Ser Tyr

ATC ATC CTC TTT TTG GTA GCA ACA GCT ACA GAT GTC CAC TCC CAG 90  
 Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp Val His Ser Gln  
 GTC CAG CTG CAA CAA CCT GGG GCT GAA CTG GTG AAG CCT GGG GCT 135  
 Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala  
 TCA GTG AAG TTG TCC TGC AAG GCT TCC GGC TAC ACC TTC ACC AGC 180  
 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr(Ser  
 CAC TGG ATG CAC TGG GTG AAG CAG AGG GCT GGA CAA GGC CTT GAG 225  
 His Trp Met His)Trp Val Lys Gln Arg Ala Gly Gln Gly Leu Glu  
 TGG ATC GGA GAG TTT AAT CCC AGC AAC GGC CGT ACT AAC TAC AAT 270  
 Trp Ile Gly(Glu Phe Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn  
 GAG AAA TTC AAG AGC AAG GCC ACA CTG ACT GTA GAC AAA TCC TCC 315  
 Glu Lys Phe Lys Ser)Lys Ala Thr Leu Thr Val Asp Lys Ser Ser  
 AGC ACA GCC TAC ATG CAA CTC AGC AGC CTG ACA TCT GAG GAC TCT 360  
 Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser  
 GCG GTC TAT TAC TGT GCC AGT CGG GAC TAT GAT TAC GAC GGA CGG 405  
 Ala Val Tyr Tyr Cys Ala Ser(Arg Asp Tyr Asp Tyr Asp Gly Arg

3'-AG TGT CAG AGG AGT  
 TAC TTT GAC TAC TGG GGC CAA GGC ACC ACT CTC ACA GTC TCC TCA 450  
 Tyr Phe Asp Tyr)Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser

BamHI  
 CCACTCACCTAGGTT-5' <----- pUC18  
 GCCAAAACAACACCCCATCGGTCTATCCACTGGAT-TCCTCTAGAGTCGACC----3' 501

## Panel B:

--- pUC18 ----->  
 5'-----TTCGAGCTCGGTACCC-ACAAAATG GAT TTT CAA GTG CAG ATT TTC 45  
 3'-----AAGCTCGAGCCATGGG-TGTTTTAC CTA AAA GTT CAC GTC--5'  
 5'-AGAAAGCTT-CCACCATG GAT TTT CAA GTG-3'  
 HindIII Met Asp Phe Gln Val Gln Ile Phe

AGC TTC CTG CTA ATC AGT GCC TCA GTC ATA CTG TCC AGA GGA CAA 90  
 Ser Phe Leu Leu Ile Ser Ala Ser Val Ile Leu Ser Arg Gly Gln  
 ATT GTT CTC ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG 135  
 Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
 GAG AAG GTC ACT ATG ACC TGC AGT GCC AGC TCA AGT GTA ACT TAC 180  
 Glu Lys Val Thr Met Thr Cys(Ser Ala Ser Ser Ser Val Thr Tyr  
 ATG TAT TGG TAC CAG CAG AAG CCA GGA TCC TCC CCC AGA CTC CTG 225  
 Met Tyr)Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu  
 ATT TAT GAC ACA TCC AAC CTG GCT TCT GGA GTC CCT GTT CGT TTC 270  
 Ile Tyr(Asp Thr Ser Asn Leu Ala Ser)Gly Val Pro Val Arg Phe  
 AGT GGC AGT GGG TCT GGG ACC TCT TAC TCT CTC ACA ATC AGC CGA 315  
 Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg  
 ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG AGT 360  
 Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys(Gln Gln Trp Ser

3'-C AAC CTT TAT TTT  
 AGT CAC ATA TTC ACG TTC GGC TCG GGG ACA AAG TTG GAA ATA AAA 405  
 Ser His Ile Phe Thr)Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
 GCACTCATCTAGATG-5' SglI  
 <----- pUC18  
 CGGGCTGATGCTGCACCAACTGTATGGATCTTCCCACCATCCAGGATCC-GGGGATCC-3' 462

$\frac{3}{12}$ 

**FIG. 3**

HindIII																
5'--AAGCTTGCCGCCACC																
Met Asp Trp Thr Trp Arg Val Phe Cys Leu																
CTC	GCC	GTG	GCT	CCT	GGG	GCC	CAC	AGC	CAG	GTG	CAA	CTA	GTG	CAG		45
Leu	Ala	Val	Ala	Pro	Gly	Ala	His	Ser	Gln	Val	Gln	Leu	Val	Gln		90
TCC	GGC	GCC	GAA	GTG	AAG	AAA	CCC	GGT	GCT	TCC	GTG	AAG	GTG	AGC		135
Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala	Ser	Val	Lys	Val	Ser		
TGT	AAA	GCT	AGC	GGT	TAT	ACC	TTC	TCT	TCC	CAC	TGG	ATG	CAT	TGG		180
Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Ser	(Ser	His	Trp	Met	His)	Trp		
GTT	AGA	CAG	GCC	CCA	GGC	CAA	GGG	CTC	GAG	TGG	GTG	GGC	GAG	TTC		225
Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Val	Gly	(Glu	Phe		
AAC	CCT	TCA	AAT	GGC	CGG	ACA	AAT	TAT	AAC	GAG	AAG	TTT	AAG	AGC		270
Asn	Pro	Ser	Asn	Gly	Arg	Thr	Asn	Tyr	Asn	Glu	Lys	Phe	Lys	Ser)		
AGG	GTT	ACC	ATG	ACC	TTG	GAC	ACC	TCT	ACA	AAC	ACC	GCC	TAC	ATG		315
Arg	Val	Thr	Met	Thr	Leu	Asp	Thr	Ser	Thr	Asn	Thr	Ala	Tyr	Met		
GAA	CTG	TCC	AGC	CTG	CGC	TCC	GAG	GAC	ACT	GCA	GTC	TAC	TAC	TGC		360
Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys		
GCC	TCA	CGG	GAT	TAC	GAT	TAC	GAT	GGC	AGA	TAC	TTC	GAC	TAT	TGG		405
Ala	Ser	(Arg	Asp	Tyr	Asp	Tyr	Asp	Gly	Arg	Tyr	Phe	Asp	Tyr)	Trp		
GGA	CAG	GGT	ACC	CTT	GTC	ACC	GTC	AGT	TCA	GGT	GAG	TGG	ATC	CAATTC		454
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser							

4/12

FIG. 4 - 1

Panel A:

<b>VL 425</b>	Gln-Ile-Val-Leu-Thr-Gln-Ser-Pro-Ala-Ile-	
<b>RVLa425</b>	Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Met-Ser-Ala-Ser-Pro-Gly-Glu-Lys-Val-Thr-	<u>FR-1</u>
<b>RVLa425</b>	Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Met-Thr-Cys	
<b>RVLa425</b>	Ile-Thr-Cys	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr	
<b>RVLa425</b>	Ser-Ala-Ser-Ser-Ser-Val-Thr-Tyr-Met-Tyr	<u>CDR-1</u>
<b>RVLb425</b>	-----	
<b>VL 425</b>	Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Ser-Ser-Pro-	
<b>RVLa425</b>	Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-	
<b>RVLb425</b>	-----	<u>FR-2</u>
<b>VL 425</b>	Arg-Leu-Leu-Ile-Tyr	
<b>RVLa425</b>	Lys-Leu-Leu-Ile-Tyr	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Asp-Thr-Ser-Asn-Leu-Ala-Ser	
<b>RVLa425</b>	Asp-Thr-Ser-Asn-Leu-Ala-Ser	<u>CDR-2</u>
<b>RVLb425</b>	-----	
<b>VL 425</b>	Gly-Val-Pro-Val-Arg-Phe-Ser-Gly-Ser-Gly-	
<b>RVLa425</b>	Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Ser-Gly-Thr-Ser-Tyr-Ser-Leu-Thr-Ile-Ser-	<u>FR-3</u>
<b>RVLa425</b>	Ser-Gly-Thr-Asp-Phe-Thr-Phe-Thr-Ile-Ser-	
<b>RVLb425</b>	-----Tyr-----	
<b>VL 425</b>	Arg-Met-Glu-Ala-Glu-Asp-Ala-Ala-Thr-Tyr-Tyr-Cys	
<b>RVLa425</b>	Ser-Leu-Gln-Pro-Glu-Asp-Ile-Ala-Thr-Tyr-Tyr-Cys	
<b>RVLb425</b>	-----	
<b>VL 425</b>	Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr	
<b>RVLa425</b>	Gln-Gln-Trp-Ser-Ser-His-Ile-Phe-Thr	<u>CDR-3</u>
<b>RVLb425</b>	-----	
<b>VL 425</b>	Phe-Gly-Ser-Gly-Thr-Lys-Leu-Glu-Ile-Lys	
<b>RVLa425</b>	Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys	<u>FR-4</u>
<b>RVLb425</b>	-----	

SUBSTITUTE SHEET

5/12

FIG. 4-2


Panel B:

V <sub>H</sub> 425	Gln-Val-Gln-Leu-Gln-Gln-Pro-Gly-Ala-Glu-	
RV <sub>H</sub> a-d, f425	Gln-Val-Gln-Leu-Val-Gln-Ser-Gly-Ala-Glu-	
RV <sub>H</sub> e, g-i425	-----	
V <sub>H</sub> 425	Leu-Val-Lys-Pro-Gly-Ala-Ser-Val-Lys-Leu-	FR-1
RV <sub>H</sub> a-d, f425	Val-Lys-Lys-Pro-Gly-Ala-Ser-Val-Lys-Val-	
RV <sub>H</sub> e, g-i425	-----	
V <sub>H</sub> 425	Ser-Cys-Lys-Ala-Ser-Gly-Tyr-Thr-Phe-Thr	
RV <sub>H</sub> a-d, f425	Ser-Cys-Lys-Ala-Ser-Gly-Tyr-Thr-Phe-Ser	
RV <sub>H</sub> e, g-i425	-----Thr	
V <sub>H</sub> 425	Ser-His-Trp-Met-His	CDR-1
RV <sub>H</sub> a-i425	Ser-His-Trp-Met-His	
V <sub>H</sub> 425	Trp-Val-Lys-Gln-Arg-Ala-Gly-Gln-Gly-Leu-	
RV <sub>H</sub> a-c, h, i425	Trp-Val-Arg-Gln-Ala-Pro-Gly-Gln-Gly-Leu-	
RV <sub>H</sub> d-g425	-----	
V <sub>H</sub> 425	Glu-Trp-Ile-Gly	FR-2
RV <sub>H</sub> a-c, h, i425	Glu-Trp-Val-Gly	
RV <sub>H</sub> d-g425	-----Ile----	
V <sub>H</sub> 425	Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-	
RV <sub>H</sub> a-i425	Glu-Phe-Asn-Pro-Ser-Asn-Gly-Arg-Thr-Asn-	
V <sub>H</sub> 425	Tyr-Asn-Glu-Lys-Phe-Lys-Ser	CDR-2
RV <sub>H</sub> a-i425	Tyr-Asn-Glu-Lys-Phe-Lys-Ser	
V <sub>H</sub> 425	Lys-Ala-Thr-Leu-Thr-Val-Asp-Lys-Ser-Ser-	
RV <sub>H</sub> a, d, e425	Arg-Val-Thr-Met-Thr-Leu-Asp-Thr-Ser-Thr-	
RV <sub>H</sub> b, h425	-----Val-----	
RV <sub>H</sub> c, f, g, i425	Lys-Ala-----Val-----	
V <sub>H</sub> 425	Ser-Thr-Ala-Tyr-Met-Gln-Leu-Ser-Ser-Leu-	FR-3
RV <sub>H</sub> a, d, e425	Asn-Thr-Ala-Tyr-Met-Glu-Leu-Ser-Ser-Leu-	
RV <sub>H</sub> a, d, e425	-----	
RV <sub>H</sub> c, f, g, i425	-----	
V <sub>H</sub> 425	Thr-Ser-Glu-Asp-Ser-Ala-Val-Tyr-Tyr-Cys-Ala-Ser	
RV <sub>H</sub> a, d, e425	Arg-Ser-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-Ser	
RV <sub>H</sub> a, d, e425	-----	
RV <sub>H</sub> c, f, g, i425	-----	
V <sub>H</sub> 425	Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr	CDR-3
RV <sub>H</sub> a-i425	Arg-Asp-Tyr-Asp-Tyr-Asp-Gly-Arg-Tyr-Phe-Asp-Tyr	
V <sub>H</sub> 425	Trp-Gly-Gln-Gly-Thr-Thr-Leu-Thr-Val-Ser-Ser	FR-4
RV <sub>H</sub> a-i425	Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser	


6/12

A

FIG. 5



B



SUBSTITUTE SHEET



7/12






FIG. 6







FIG. 9A

10/12






FIG. 9B



SUBSTITUTE SHEET

FIG. 10


11/12



SUBSTITUTE SHEET

FIG. 11

12/12



<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	C 12 N 15/13	C 07 K 13/00 C 12 N 15/62
C 12 P 21/08	A 61 K 39/395	A 61 K 49/00
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	Journal of Molecular Biology, vol. 215, no. 1, 5 September 1990, A. TRAMONTANO et al.: "Framework residues 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins", pages 175-182, see paragraph 7: "Conclusion"	1-3
Y	---	4-25
Y	Arch. Biochem. Biophys., vol. 252, no. 2, 1 February 1987, U. MURTHY et al.: "Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide", pages 549-560, see the whole document (cited in the application) --- -/-	4-25
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03-06-1992	30. 06. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Nicole De Bie	

## III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	Science, vol. 239, 25 March 1988, M. VERHOEYEN et al.: "Reshaping human antibodies: grafting an antilysozyme activity", pages 1534-1536, see the whole document, especially figures 1c,2 (cited in the application)	1-3
Y	---	4-25
Y	J. Cell. Biochem., vol. 44, no. 2, October 1990, U. RODECK et al.: "Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha", pages 69-79	4-25
X	Proc. Natl. Acad. Sci. USA, vol. 86, December 1989, C. QUEEN et al.: "A humanized antibody that binds to the interleukin 2 receptor", pages 10029-10033, see the whole document (cited in the application)	1-3
Y	---	4-25
P,X	Protein Eng., vol. 4, no. 7, October 1991, C.A. KETTLEBOROUGH et al.: "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation", see the whole document	1-25
A	Nature, vol. 342, 21/28 December 1989, C. CHOTHIA et al.: "Conformations of immunoglobulin hypervariable regions", pages 877-883 (cited in the application)	1-25
A	Cancer Res., vol. 47, no. 10, 15 May 1987, A. BASU et al.: "Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas", pages 2531-2536	



## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 25 is directed to diagnostic methods practised on the human body (Rule 39.1(IV) PCT) the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.